Utah State University

DigitalCommons@USU
All Graduate Theses and Dissertations

Graduate Studies

5-2017

Impact of Antidementia Medications on Neuropsychiatric
Symptoms and Informal Costs of Caregiving in Dementia
Stephanie Behrens
Utah State University

Follow this and additional works at: https://digitalcommons.usu.edu/etd
Part of the Psychology Commons

Recommended Citation
Behrens, Stephanie, "Impact of Antidementia Medications on Neuropsychiatric Symptoms and Informal
Costs of Caregiving in Dementia" (2017). All Graduate Theses and Dissertations. 5609.
https://digitalcommons.usu.edu/etd/5609

This Thesis is brought to you for free and open access by
the Graduate Studies at DigitalCommons@USU. It has
been accepted for inclusion in All Graduate Theses and
Dissertations by an authorized administrator of
DigitalCommons@USU. For more information, please
contact digitalcommons@usu.edu.

IMPACT OF ANTIDEMENTIA MEDICATIONS ON NEUROPSYCHIATRIC
SYMPTOMS AND INFORMAL COSTS OF CAREGIVING IN DEMENTIA
by
Stephanie Behrens
A thesis submitted in partial fulfillment
of the requirements for the degree
of
MASTER OF SCIENCE
in
Psychology
Approved:

JoAnn T. Tschanz, Ph.D.
Major Professor

Gail B. Rattinger, Pharm.D.
Committee Member

M. Scott DeBerard, Ph.D.
Committee Member

Mark R. McLellan, Ph.D.
Vice President for Research and
Dean of the School of Graduate Studies
UTAH STATE UNIVERSITY
Logan, Utah
2017

ii

Copyright © Stephanie Behrens 2017
All Rights Reserved

iii
ABSTRACT
Impact of Antidementia Medications on Neuropsychiatric Symptoms and
Informal Costs of Caregiving in Dementia
by
Stephanie Behrens, Master of Science
Utah State University, 2017
Major Professor: JoAnn T. Tschanz, Ph.D.
Department: Psychology
To date, the most common pharmacological treatments for dementia are
cholinesterase inhibitors and N-methyl-D-aspartate receptor antagonists (antidementia
medications), which are associated with a delay in the progression of the cognitive and
functional symptoms. Studies of the effects of antidementia medications on
neuropsychological symptoms (NPS) show varying results. Presence of NPS can also
affect the amount of time caregivers spend with persons with dementia, which can affect
informal costs of the condition. This project used extant data from the longitudinal,
population-based Cache County Study on Memory and Aging (CCSMA) and the
Dementia Progression Study (DPS), which included permanent residents aged ≥ 65 of
Cache County, Utah. Linear mixed models were used to assess the association between
antidementia medications with informal costs and NPS. The first study examined whether
antidementia medications were associated with a decrease in informal costs. Use of
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antidementia medications was not significantly associated with informal costs (expβ =
.79, p = .090). When restricting the sample to only the participants who were of mild
dementia severity at baseline, antidementia medications were associated with a 28%
decrease in informal costs (expβ = .72, p = .039). The second study evaluated whether
antidementia medications were associated with a decrease in NPS. Results indicated that
use of antidementia medications was associated with a 28% increase in NPS (expβ =
1.28, p < .001). However, this association was no longer significant with the inclusion of
covariates, in particular, the use of psychotropic medications. Use of any psychotropic
medication was significantly associated with a 30% increase in Neuropsychiatric
Inventory (NPI) score. Overall, the use of antidementia medications may not significantly
reduce informal costs or NPS. The use of antidementia medications may reflect patterns
of use that are prompted by severity of dementia and NPS.
(130 pages)
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PUBLIC ABSTRACT
Impact of Antidementia Medications on Neuropsychiatric Symptoms and
Informal Costs of Caregiving in Dementia
by
Stephanie Behrens
Dementia-related diseases are progressive neurological disorders that can affect a
person’s cognition and functional abilities, and also result in mental health symptoms
commonly called neuropsychiatric symptoms (NPS). To date, the most common
pharmacological treatments for dementia, “antidementia” medications, delay the
progression of the cognitive and functional symptoms of the condition. Studies of the
effects of antidementia medications on NPS show varying results. Presence of NPS can
also affect the amount of time caregivers provide care with persons with dementia, which
can affect informal costs of the condition. This project used extant data from the
longitudinal, population-based Cache County Study on Memory and Aging (CCSMA;
1994-2007) and the Dementia Progression Study (DPS; 2002-2013), which included
permanent residents aged 65 years and above in 1995 in Cache County, Utah. Both of
these studies were funded by grants through the National Institute on Aging, with
participants and caregivers receiving $25 for each visit. Linear mixed models were used
to assess the association between antidementia medications with informal costs and NPS.
The first study examined whether use of antidementia medications was associated with a
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decrease in informal costs. The median daily informal cost of care by dementia severity
was as follows: cost for mild dementia was $9.92, cost for moderate dementia was
$30.02, and cost for severe dementia was $46.99. Antidementia medication use was not
associated with informal costs (expβ = .79, p = .090); however, when restricting the
sample to only the participants who were of mild dementia severity at baseline,
antidementia medications were associated with a 28% decrease in informal costs (p =
.039).
The second study evaluated if antidementia medications was associated with a
decrease in NPS. Use of antidementia medications was associated with a 28% increase in
NPS (expβ = 1.28, p < .001). However, this association was no longer significant with the
inclusion of covariates, in particular, the use of psychotropic medications. Use of
psychotropic medications was significantly associated with a 30% increase in NPS.
Compared to mild dementia severity, moderate CDR was significantly associated with a
49% increase in NPS and severe CDR was significantly associated with a 60% increase
in NPS. Overall, the use of antidementia medications may not significantly reduce
informal costs or NPS. These studies suggest that persons who use antidementia (and
psychotropic medications) are more likely to be experiencing more severe symptoms of
dementia. Future work exploring patterns in the initiation and duration of use may be
helpful to further examine the potential beneficial effects of these treatments.
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CHAPTER 1
INTRODUCTION
Dementia-related diseases affect approximately 46.8 million individuals
Alzheimer’s Disease International [ADI], 2015). These numbers are projected to double
every 20 years, resulting in estimates of 131.5 million individuals with the disease in
2050 (ADI, 2009, 2015). With the current prevalence of dementia, the 2015 worldwide
total cost of the disease was estimated at U.S. $818 billion and is projected to increase to
two trillion dollars by 2030 (ADI, 2013). The costs of care for dementia related diseases
can be broken down into formal and informal costs, with informal costs being the focus
of the present study.
Formal costs of dementia are defined as the act of paying for services, such as
healthcare, full-time professional care, and medications. Informal costs are administered
aid where no money is exchanged but where there is a loss of income or leisure time of
the person administering care (Gillespie et al., 2013; Hurd, Martorell, Delavande, Mullen,
& Langa, 2013; Langa et al., 2001). Family members typically incur informal costs as
unpaid caregivers. The informal costs of care for persons with dementia living in the
community are estimated to account for approximately 70%-80% of the total costs of the
disease (Rapp et al., 2012; Schwarzkopf et al., 2011). The high use of informal care
emphasizes how the economic impact of dementia would increase astronomically if
unpaid caregivers did not provide the majority of care.
Extensive research is taking place to develop treatments for dementia in order to
decrease the economic and emotional costs associated with the condition. The most
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common pharmacological treatments to date are “antidementia” medications,
cholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists, which
delay the progression of the cognitive and functional symptoms of the condition.
According to Hartz, Getsios, Tao, Blume, and Maclaine (2012), a study in Germany
found antidementia medications, donepezil and memantine, to be cost effective for the
total cost of Alzheimer’s disease when compared to no treatment. The cost effectiveness
concerned improving the cognitive and functional status of the individual, decreasing the
severity of the disease, and delaying institutionalization. Although the benefits of taking
antidementia medications have been well documented, a majority of the studies have
relied on clinic-based samples followed for a limited time period (i.e., a few months)
(Burns et al., 2009; Burns, Spiegel, & Quarg, 2004; Hashimoto, Yatabe, Kaneda, Honda,
& Ikeda, 2009; Rive et al., 2012). Since dementia is progressive, the short period of study
poses a problem when generalizing results to individuals at various stages and lengths of
illness. Results of clinical trials may also be limited in generalizability due to strict
eligibility criteria.
While the beneficial effects of antidementia medications on cognitive and
functional impairments appear to be a common finding across studies, studies of
antidementia medications and neuropsychiatric symptoms (NPS) show varying results.
Some studies show no effects of antidementia medications on reducing NPS (Hellweg,
Wirth, Janetzky, & Hartmann, 2012), while other studies show antidementia medications
to have moderate effects in reducing NPS (Grimmer & Kurz, 2006). NPS are significant
features of dementia, in their nearly universal occurrence (Cummings, Mackell, &
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Kaufer, 2008; Tschanz et al., 2011), their major effects on caregiver burden (Allegri et
al., 2006; Rymer et al., 2002), and the informal costs of care (Rattinger et al., 2015).
Based on the current literature, it is unclear whether antidementia medications effectively
reduce the occurrence or severity of NPS, and whether this in turn decreases informal
care needs and informal costs of the condition.
The purpose of this project was to evaluate how antidementia medications affect
the occurrence and severity of NPS and the costs of informal dementia care. The present
study examined a community-, population-based sample of persons with dementia
followed for up to 10 years, with most individuals being followed from a few years of
dementia onset up to their deaths. In Study 1 of the project, I examined whether treatment
with antidementia medications was associated with lower informal care costs in dementia
related-diseases and in Study 2, I examined whether treatment with antidementia
medications was associated with less severe NPS in persons with dementia.
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CHAPTER 2
STUDY 1: INFORMAL COSTS AND ANTIDEMENITA MEDICATIONS

Abstract
Antidementia medications (cholinesterase inhibitors and N-methyl-Daspartate receptor antagonists) are associated with a delay in the progression of dementia
symptoms. The severity of dementia symptoms (cognitive, functional,
neuropsychological) can affect the informal cost of the condition. This project included
277 participants with dementia from the longitudinal, population-based Dementia
Progression Study (DPS), which is the ancillary study to the Cache County Study on
Memory and Aging (CCSMA). Medication use was based on inspection of each
participant’s medications and interview, and caregiving hours were estimated using the
Caregiver Activity Survey. Informal costs were calculated using the replacement cost
method by multiplying hours of care by Utahan median wages in the visit year, then
adjusted for inflation and expressed in 2015 dollars. Linear mixed models, using the
gamma log-link function, assessed the association between antidementia medications
with informal costs. The median daily informal cost of dementia care by severity of
dementia was as follows: mild dementia was $9.92, moderate dementia was $30.02, and
severe dementia was $46.99. Use of antidementia medications was not significantly
associated with informal costs (expβ = .79, p = .090). When restricting the sample to only
the participants who were of mild dementia severity at baseline, antidementia
medications were associated with a 28% decrease in informal costs (expβ = .72, p =
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.039). The use of antidementia medications significantly reduces informal costs when
started at earlier dementia severity stages.

Introduction
With the prevalence of dementia-related diseases increasing exponentially, the
global costs associated with the condition are also increasing. In the U.S., the costs of
Alzheimer’s dementia, not adjusting for coexisting health conditions, was estimated at
$203 billion in 2013. These costs can be broken down into costs to public and private
sectors of the economy including $113 billion from Medicare, $41 billion from Medicaid,
$44 billion from out-of-pocket costs, and $29 billion from other payment sources (“2015
Alzheimer’s facts and figures,” 2015). If current trends continue, the costs of dementia
are projected to increase approximately 80% to one trillion in U.S. dollars (2015) by 2050
(ADI, 2013; “2015 Alzheimer’s facts and figures,” 2015; Hurd et al., 2013).
The cost estimates for dementia include the costs of a wide range of services
provided for the individuals and their families, and can be broken down into the
categories of formal or informal costs. The formal costs of dementia are derived from
formal care and can be broken down into broad categories of medical care, full-time
professional care, and medications. From a societal perspective the total cost for dementia
per U.S. citizen was estimated at approximately $41,689 in 2014 dollars (“2014
Alzheimer’s Facts and Figures,” 2014). Formal costs of dementia in the U.S. include
public payers such as Medicare, Medicaid, and other public entities provided by state or
local governments. According to the “2014 Alzheimer’s Facts and Figures” 2014), the
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average Medicare costs for persons with dementia was three times higher than their
similar aged peers without dementia, and the average Medicaid costs, including nursing
home care, for persons with dementia in 2014 was 19 times higher (“2014 Alzheimer’s
Facts and Figures,” 2014; “2015 Alzheimer’s facts and figures,” 2015). If current trends
continue, it is estimated that by 2050, Medicare and Medicaid costs could increase by
500% (“2014 Alzheimer’s Facts and Figures,” 2014). Within Medicare and Medicaid
spending, the largest component generally has been attributed to institutionalized care,
which is estimated to exceed Medicare and Medicaid costs by 2 to 3 times those of
persons living in the community (Leon, Cheng, & Neumann, 1998). Estimates show that
Medicare and Medicaid pay approximately 70% of the costs of institutional care of
dementia (Lin et al., 2013), with Medicare and Medicaid paying the average annual cost
of U.S. $33,544 2015 per person (“2016 Alzheimer’s facts and figures,” 2016). Studies
on the economic impact of dementia have been studied to a greater degree in European
countries. While such studies can offer insights on sources of costs, estimates may not be
generalizable to the U.S. due to differences in culture, economics, and health care
systems. Thus for U.S. data, the majority of cost estimates are based on data from large
insurance databases such as Medicare; however, as where dementia is identified through
claims data, such an approach tends to overlook milder cases of dementia (Taylor,
Ostbye, Langa, Weir, & Plassman, 2009).

Informal Costs
Informal care is aid administered by family members or others who are not
reimbursed for their services. Informal family caregivers provide about 83% of home
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care for people with dementia (“2016 Alzheimer’s facts and figures,” 2016). In the U.S.
in 2015, 18.1 billon hours of informal care was provided to persons with dementia, which
was valued at $221.3 billion 2015 U.S. dollars (“2016 Alzheimer’s facts and figures,”
2016).
Several approaches have been used to calculate informal costs of dementia care,
including forgone wages/lost earnings, opportunity costs, and replacement wages.
Forgone wages/lost earnings are calculated by using the wages the caregiver would have
received if employed, opportunity costs are measured by the value of lost income as well
as lost leisure time of the caregivers, and replacement wages are measured by the wage a
paid professional would have been given to provide care if the caregiver was unable to
(Fillit & Hill, 2004; Gillespie et al., 2013; Hurd et al., 2013; Langa et al., 2001; Leicht et
al., 2011; Moore, Zhu, & Clipp, 2001; Murman & Colenda, 2005). Forgone wages and
lost earnings are appropriate for calculating informal costs when the caregiver is
employed, while opportunity costs may be more appropriate for calculating informal
costs of a retired caregiver. In a review of the economic impact of AD, it was suggested
that the lost earnings method might underestimate the economic impact of informal care
because this method does not calculate informal cost estimates for caregivers who are not
in the work force (e.g., retired spouse; Murman & Colenda, 2005). Fillit and Hill
suggested that different approaches may be better for estimating costs based on the
caregivers’ situation. The opportunity cost approach puts value on the caregiver’s time
and is considered the best approach for caregivers who are employed and likely
sacrificing hours at work to be a caregiver (Fillit & Hill, 2004). Replacement wages
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assume that if there was not an informal caregiver providing services, the individual with
dementia would need formal services, for example, nursing or home health services. For
unemployed caregivers, the review found that the replacement wages approach was
commonly used to estimate informal costs (Fillit & Hill, 2004), and this approach was
used recently in the Cache County Dementia Progression Study in a sample consisting of
both employed and unemployed/retired caregivers (Rattinger et al., 2015).

Estimates of Informal Costs
There is a limited body of literature on the informal costs of dementia care in the
U.S. One of the first published U.S. studies used the Asset and Health Dynamics
(AHEAD) data, which is comprised of community dwelling individuals. They employed
the 1998 national average wage for a home heath aid (mean wage of $8.20 per hour) and
found a yearly cost of $3,630 for mild dementia, which rose to $17,700 for severe
dementia (Langa et al., 2001). In further exploring variations in costs, the authors used a
range of wages from the 10th percentile of the national home health aids wage of $5.90 to
the 90th percentile wage of $10.80 (Langa et al., 2001). At the low end, mild dementia
cost $2,610 per year and severe dementia cost $12,730 per year, while at the upper end,
mild dementia cost $4,780 per year and severe dementia cost $23,310 per year in 2001
dollars (Langa et al., 2001). While a strength of this study was a national populationbased sample, no information was available on potential modifiers of informal costs, such
as neuropsychiatric symptoms (NPS) and comorbidities. Additionally, costs were based
on cross-sectional analysis in that longitudinal data were not available.
Another U.S. cost study enrolled male veterans living in the community (Moore et
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al., 2001). Using the replacement wage approach, the authors applied the market price for
various types of formal care services including physical care, personal management, and
housekeeping (Moore et al., 2001). Estimated weekly informal costs, in 1998 dollars
ranged from $45 when the care recipient had no impairment in activities of daily living
(ADL) to $270 when the care recipient was not able to perform any ADLs (Moore et al.,
2001). The study also calculated the caregivers’ lost earnings with the average annual
loss of $10,709, which between $10,000 to $12,000 per year as dementia progressed
(Moore et al., 2001). Study limitations included the cross-sectional nature and the
restricted nature of the sample.
More recently, Hurd et al. (2013) compared informal cost estimates of forgone
wages and replacement wages in a nationally representative U.S. sample from the Health
and Retirement Study (HRS). The advantage of using forgone wages lay in the
assumption that caregivers were presumably giving up time at their jobs to assist the
individual with dementia. The forgone wage for employed caregivers was estimated by
the caregiver’s self-reported wages and for caregivers who were not employed, their
forgone wages were calculated by averaging wages for persons with similar demographic
characteristics (age, sex, and education level; Hurd et al., 2013). Replacement costs of
informal care were calculated by using the market cost of the equivalent services
purchased through a home health agency. After controlling for comorbidities, costs based
on annual forgone wages were estimated at $41,689 (with 95% CI, $31,017 to $52,362)
and costs based on replacement wages were estimated at $56,290 (with 95% CI, $42,746
to $69,834) based on the 2010-dollar value (Hurd et al., 2013). Estimates of unpaid
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caregiving revealed forgone wages accounted for 31% of the total cost while replacement
wages accounted for 49% of the total cost (Hurd et al., 2013). In addition to using two
methods to calculate informal costs, the other strengths of the study included the large
representative sample. However, indicators of dementia severity were not available.
Apart from the AHEAD and the veterans study, few U.S. studies have examined
modifiers of the informal costs of dementia care. More information is available from
international studies. The German Initiative Demenzversorgung in der Allgemeinmedizin
(IDA) project evaluated overall costs of 383 individuals with mild and moderate
dementia living in the community (Schwarzkopf et al., 2011). The average annual cost
for individuals with mild dementia in 2008 was €30,803 and for individuals with
moderate dementia was €52,335, controlling for age and gender (Schwarzkopf et al.,
2011). In this sample, informal care was 4-fold the cost of formal care and accounted for
approximately 80% of total costs (Schwarzkopf et al., 2011).
Dementia severity measured by cognitive and functional impairments was
examined in a 2-year longitudinal study of 1,131 community dwelling French individuals
with AD (Rapp et al., 2012). In this study, informal costs were estimated by caregiver
time spent on surveillance, ADL, and instrumental activities of daily living (IADL).
Formal medical costs were measured by any hospital or clinic visit, and medication costs
and the formal non-medical costs were measured by day care, alarm services, and home
help (Rapp et al., 2012). Cognitive decline significantly impacted informal costs more
than medical and non-medical costs, and functional decline impacted formal non-medical
costs more than formal medical and informal costs. All analyses controlled for care-
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recipient age at baseline, gender, education, time since AD diagnosis, and caregiver
gender (Rapp et al., 2012). These results suggest that mild stages of dementia tend to cost
more for informal care, but with the onset of ADL impairment, the cost burden switches
to formal costs. This study also found mild AD was the source of the most expensive
informal costs (Rapp et al., 2012). By contrast, a 2-year German longitudinal study of
175 persons with dementia found IADL impairment to be a stronger predicator of
informal costs than cognitive impairment (Leicht et al., 2013). However, since IADL
impairments are usually present at earlier stages of AD and personal ADL impairments in
mid-to-late stages, these results also support the observation that impairment in functional
abilities also drive informal costs early in the disease course.
NPS may also affect the costs of dementia care. A Swedish study consisting of 92
dyads of persons with dementia and their caregivers, evaluated how time was spent in
informal caregiving [e.g. assisting with ADLs, IADLs, and supervision or surveillance
(Wimo, Von Strauss, Nordberg, Sassi, & Johansson, 2002)]. Results found that
supervision or surveillance constituted a large part of informal care, particularly in cases
of moderate dementia severity and also in cases with high amounts of NPS (Wimo et al.,
2002). Beeri, Werner, Davidson, and Noy (2002) showed approximately 30% of total
costs and 65% of informal costs were attributable to managing NPS in community
dwelling individuals with AD in Israel. A Canadian study of 500 individuals and their
caregivers found that even with mild dementia, the presence of NPS increased the cost of
care dementia care, and in particular, informal costs (Herrmann et al., 2006). While this
study found that NPS contribute to higher costs, the authors did not calculate what these
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costs were and if they were statistically significant compared to the absence of NPS
(Herrmann et al., 2006).
A U.S. study examined a representative sample (The Aging, Demographics, and
Memory Study-ADAMS) of the HRS (Okura & Langa, 2011). When compared to
individuals without NPS, individuals with one to two NPS had an increase of 10 hours of
informal care per week with an additional 12.4 hours of supervision; individuals with
three or more NPS had an increase of 18.2 hours of informal care with an additional 28.7
hours of supervision (Okura & Langa, 2011). The NPS associated with the highest
informal care hours were agitation, anxiety or irritation, depression, disinhibition, and
aberrant motor behaviors (Okura & Langa, 2011). The positive association between NPS
and hours of informal care remained even after adjusting for cognitive deficits and
medical comorbidities, but not medication use (Okura & Langa, 2011). Limitations to the
preceding studies is their cross-sectional nature, or with respect to the international
studies, the short study period (e.g., 6 months to 1 year).
Two U.S. longitudinal studies examined the effects of NPS and the informal costs
of dementia care. The U.S. Predictors Study enrolled 204 persons with AD from three
university-based research clinics and followed them longitudinally from 1990 to 2004
(Zhu et al., 2006a). This study found that cognitive and functional abilities were
associated with informal costs, but no association between NPS and informal costs. The
authors attributed this to the crude measurements of the NPS, which was dichotomously
measured by the presence or absence of psychiatric symptoms, depressive symptoms, and
behavioral problems (Zhu et al., 2006a). While one of this study’s strength was the long
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follow-up time, the participants represented a unique sample of AD patients treated at
university dementia clinics, and thus results may not generalize to other populations. In a
population-based sample from the Cache County Dementia Progression Study, Rattinger
and colleagues found that when controlling for cognitive impairment, more severe NPS
was associated increased informal care costs. This finding raises the possibility that the
treatment of NPS may reduce informal costs (Rattinger et al., 2015).
With the informal costs of dementia care increasing with severity of dementia and
possibly NPS, it is unclear if dementia treatments reduce costs. In 1993, the U.S. Food
and Drug Administration (FDA) approved the first antidementia medication, tacrine, a
cholinesterase inhibitor (ChEI). Due to adverse side effects, it is no longer on the market
(Atri, 2011). Several antidementia medications have since received FDA-approval
including the cholinesterase inhibitors (ChEIs) donepezil (Aricept), galantamine
(Razadyne), rivastigmine (Exelon), and an N-methyl-D-aspartate (NMDA) receptor
antagonist, memantine (Namenda; Atri, 2011). To date, there has not been substantial
evidence to show superior efficacy of one ChEI over another, but studies have shown
combination treatment (ChEI + memantine) is advantageous over monotherapy (ChEI
alone; Atri, 2011).
Rountree, Atri, Lopez, and Doody (2013) reported that in short-term randomized
controlled trials (RCTs) ranging from six months to one year, antidementia medications
improved or decreased the rate of cognitive decline in AD and that long-term
observational controlled (LTOC) studies found that persistence of medication use
reduced cognitive, functional, and global decline (Rountree et al., 2013). The results from
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these studies also showed that combination therapy including memantine was superior to
ChEI monotherapy (Rountree et al., 2013).
The use of antidementia medications may also reduce NPS (Grimmer & Kurz, 2006;
Rodda, Morgan, & Walker, 2009), which together with their cognitive and functional
effects may in turn affect time spent caregiving and caregiving burden, which may
potentially reduce indirect costs.
The purpose of this study was to examine whether the use of antidementia
medications is associated with lower informal care costs in the population-based study,
the Cache County Dementia Progression Study. This study’s sample has several
advantages including the enrollment of community dwelling individuals and high
participation rates with follow-up up to 10 years. Particularly, the longitudinal nature of
this study allows for disease severity to be included as a factor when estimating informal
cost.

Methods

Sample
This project used extant data from the Dementia Progression Study (DPS; 2002 –
2013), which enrolled and followed persons with dementia identified from the
longitudinal, population-based Cache County Study on Memory and Aging (CCSMA).
The CCSMA included permanent residents of the county aged ≥ 65 years in 1995, and
examined the prevalence, incidence, and risk factors of dementia in this U.S. county. In
Wave 1, CCSMA enrolled 5,092 (89.7%) of the eligible individuals in the county
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(Breitner et al., 1999) and subsequently conducted three additional triennial waves of
dementia screening and evaluation described briefly below.
In the first stage of CCSMA screening, participants were given the 100-point
Modified Mini-Mental State Examination (3MS) cognitive screener or if unable, a proxy
informant completed the Informant Questionnaire for Cognitive Decline (IQCODE;
(Jorm, Scott, & Jacomb, 1989)). If an individual’s 3MS score was below 87, if the
IQCODE was > 4.23, or if he/she was a member of a designated subsample to complete
all evaluation stages, a knowledgeable informant completed a dementia questionnaire
(DQ) with a technician. The DQ is a 50-item semistructured interview on dementia
symptoms and general medical history, the results of which were then rated for degree of
cognitive impairment by a neuropsychologist and geriatric psychiatrist. Individuals with
ratings of questionable or probable dementia were asked to undergo a clinical assessment,
which was conducted by a research nurse and psychometrist. In the clinical assessment,
the research nurse evaluated the participant’s medical history and current medications
with an informant and completed blood pressure measurement and a standardized
neurological examination with the participant. The psychometrist administered a battery
of neuropsychological tests (Tschanz et al., 2000) to the participant. Additionally, a
knowledgeable informant completed the Neuropsychiatric Inventory (NPI).
As described previously (Breitner et al, 1999), a neuropsychologist, geriatric
psychiatrist, and examining nurse and psychometrist reviewed the clinical assessment
results. A preliminary diagnosis of dementia was given if symptoms met the criteria from
the Diagnostic and Statistical Manual-III-R (DSM-III-R; American Psychological
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Association [APA], 1987). Individuals, who received a classification of dementia or
“mild/ambiguous” (a state designating prodromal AD), were sent for follow-up
laboratory testing and neuroimaging (complete blood counts, routine chemistries, serum
B-12, folate, thyroid function test, urinalysis, and Magnetic Resonance Imagining (MRI)
or Computed Tomography (CT) scan. Persons with suspected dementia were examined in
their residence by a geriatric psychiatrist or neurologist who repeated the neurologic
examination, Mini-Mental State Exam (MMSE), and clinical history. After a review of
all available clinical exams, a panel of expert clinicians consisting of geriatric
psychiatrists, a neurologist, neuropsychologists, and a cognitive neuroscientist assigned a
final diagnosis. A diagnosis of AD was assigned according to criteria of the National
Institute of Neurological and Communicative Diseases and Stroke-Alzheimer’s Disease
and Related Disorders Association (NINCDS-ADRDA). A Vascular Dementia (VaD)
diagnosis was given based on the National Institute of Neurological Disorders and
Stroke-Association Internationale pour la Recherche et l’Enseignement en Neurosciences
(NINDS-AIREN) criteria. Diagnoses of other dementias followed standard research
criteria. Additionally, age of dementia onset (age at which the individual met DSM-III-R
criteria for dementia), severity of dementia using the Clinical Dementia Rating (CDR;
Hughes, Berg, Danzinger, Coben, and Martin (1982), and rating of overall health with the
General Medical Health Rating (GMHR; Lyketsos et al., 2005) were assigned. Persons
with dementia completed a clinical assessment 18 months later to clarify the diagnosis
(Breitner et al., 1999).
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Procedures
From 2002 to 2007, the individuals who were identified with incident dementia
(newly onset at each wave) in the CCSMA and their caregivers were invited to participate
in the DPS (Tschanz et al., 2011). The DPS was a longitudinal study running from 2002
to 2013 and examined factors that affected the rate of dementia progression in persons
with dementia. A research nurse and psychometrician conducted in-home evaluations of
the participants and their caregivers approximately every 6 to 8 months. The in-home
evaluations consisted of a 45- to 60-minute neuropsychological test battery, brief
neurological and physical examination, assessment of functional abilities using the CDR
and Dementia Severity Rating Scale (DSRS; Clark & Ewbank, 1996), interview of health
and psychiatric conditions, medication review and assessment of the caregiver’s wellbeing and time spent providing care (Tschanz et al., 2011).
Outcome variable. The Caregiver Activity Survey (CAS; Appendix E) was used
as a basis to estimate informal costs of dementia care across all caregivers (Davis et al.,
1997). The CAS was administered to the caregiver annually at alternating (odd
numbered) visits in the DPS. The CAS has a total of six items, which assess how much
assistance over the last 24 hours all caregivers provided the individual with dementia
(Davis et al., 1997). These tasks included communicating with the person, using
transportation, eating, dressing, supervising, and looking after one’s appearance (Davis et
al., 1997). The items were summed together to yield a total. This project imposed a
maximum of 16 hours per day, allowing for eight hours of sleep as done in previous
research (Penrod, Kane, Finch, & Kane, 1998; Zhu et al., 2006b). The CAS has high test–
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retest reliability, with ICC = .88 as reported previously (Davis et al., 1997). The CAS
also has strong convergent validity with measures of cognitive ability including the
Alzheimer’s Disease Assessment Scale-Cognitive (ADAS-Cog), r = .61 and the MMSE,
r = -0.57 (Davis et al., 1997). This is similar to the longitudinal findings of the CAS with
significant correlations with the MMSE, r = -.58 and the ADAS cognitive subscale, r =
.56 (Marin et al., 2000).
An estimate of informal costs was calculated using the hours reported on the CAS
using the replacement wages method. Replacement wages (Hurd et al., 2013) were
calculated by assigning values to the services from the cost equivalent of the median
wage of Utahans in the year of the visit, consistent with the approach used in this sample
by Rattinger et al. (2015). DPS did not obtain data on each caregiver’s salary so that
estimates for forgone wages or opportunity costs could not be calculated. Also consistent
with Rattinger et al., the Medical Consumer Price Index (MCPI) multiplier, which is
based on the annual average of “medical care services” from the Urban Consumer Price
Index (CPI-U), was used to account for changes in market price over the years of data
collection of the study (2002-2012; U.S. Department of Labor, Bureau of Labor
Statistics, 2016). For example, of the conversion of 2002 Utah median hourly wage into
2015 dollars 2002 MCPI was calculated by dividing the 2015 CPI-U annual average of
476.171 by the 2002 CPI-U annual average of 292.9 (476.171/292.9 = 1.626). The
resulting value (1.626) was multiplied by the 2002 median Utah hourly wage of $12.23
totaling $19.88. Table 2.1 outlines the values that were obtained through the U.S. Bureau
of Labor’s Statistics including medium wage and the CPI-U (U.S. Department of Labor,
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Table 2.1
Median Wage in Utah Per Year and Consumer Price Index
Year

Median Wage

2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012

12.23
12.45
12.69
12.94
13.46
13.99
14.48
14.79
15.04
15.41
15.75

Urban consumer
price index
1.63
1.56
1.48
1.41
1.36
1.29
1.24
1.20
1.16
1.12
1.08

2016; U.S. Department of Labor, Bureau of Labor Statistics, 2016).
Predictor variables. At each visit, medication use was recorded by the research
nurse who inspected the medicine chest for each participant following methods described
previously (Medication Record; Appendix A; Zandi, 2005). Because information on
medication use between visits was not available, medications used at consecutive visits
were assumed to be taken continuously between visits. Medications were reviewed and
coded using the Mosby Drug Reference System (Skidmore-Roth, 2009).
Medications of interest included antidementia medications, psychotropic
medications, and medications with anticholinergic properties. The latter two categories
were included as covariates in statistical analyses due to their effects on NPS or
cognition, and therefore potentially affecting informal costs. Subjects were classified
according to use of antidementia medication (CHEIs or NMDA receptor antagonists) as
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currently using vs. not currently using. Antidementia medications were used in the
analysis to evaluate the effects on informal costs. The psychotropic medication classes
included antidepressants, antipsychotics, mood stabilizers and sedatives, hypnotics, and
anxiolytics. The antidepressant drugs included selective serotonin reuptake inhibitors
(e.g. citalopram), selective norepinephrine reuptake inhibitors (e.g. mirtazapine),
monoamine oxidase inhibitors (e.g. phenelzine), tricyclics (e.g. amitriptyline), and other
antidepressants (e.g. maprotiline). Antipsychotic medications consisted of first generation
(e.g. haloperidol) and second generation (e.g. quetiapine). The sedatives, hypnotics, and
anxiolytics included were barbiturates (e.g. pentobarbital) and benzodiazepines (e.g.
flurazepam), and the mood stabilizers included were lithium, carbamazepine, lamotrigine,
and valproic acid.
Psychotropic medications were included as a covariate because their use may
diminish NPS, and therefore potentially be associated with informal costs. These
psychotropic drug classes were condensed into a current vs. not current use. Medications
with anticholinergic properties were classified using The Anticholinergic Cognitive
Burden Scale (ACBS, 2012; see Appendix B. The ACBS is a list of anticholinergic
medications ranked from 1 to 3, with level 1 meaning possible anticholinergic effects and
levels 2 and 3 indicating definite anticholinergic effects (Campbell et al., 2010).
Medications classified as having level two or three anticholinergic effects were used as a
covariate as either current or not current use at each visit. Anticholinergic medications
were included as a covariate because of potential adverse effects on cognition, which also
may be associated with informal costs (Carriere et al., 2009).
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Additional covariates included the CDR (Appendix C), which is a rating scale
completed by the nurse and based on a semi-structured interview administered every visit
to the caregiver and participant to estimate the severity of cognitive and functional
impairments across six domains: memory, orientation, judgment and problem solving,
community affairs, home and hobbies, and personal care (Hughes et al., 1982). The CDR
global scoring method involves a scale ranging from 0 = no impairment, 0.5 =
questionable impairment, 1 = mild impairment 2 = moderate impairment, 3 = severe
impairment, 4 = profound impairment, and 5 = terminal, while the CDR Sum of Boxes
(CDR-SB) is calculated by adding all of the domain scores together to create a total score
ranging from 0 = no impairment to 18 = severe impairment (Hughes et al., 1982;
O'Bryant et al., 2010). Due to limited number of participants rated in the extremes (e.g.,
very mild or severe), the data were collapsed into the following ranges 0, .5, 1 = mild
impairment, 2 = moderate impairment, 3, 4, 5 = severe impairment. The overall interrater reliability of the CDR has been reported as moderate to high with a kappa = 0.62
(Rockwood, Strang, MacKnight, Downer, & Morris, 2000).
Overall health status was also used as a covariate, and assessed using the General
Medical Health Rating (GMHR, see Appendix D), which provides a global rating of an
individual’s health. The rating is based on information obtained at each visit from the
medical interviews conducted by the research nurse, a review of medications and brief
physical and neurological exams (Lyketsos et al., 2005). In assigning the ratings,
consideration is given to the number of conditions, acute or chronic status, and whether
the conditions are controlled by treatments (Lyketsos et al., 2005). Based on this

22
information, a geriatric psychiatrist and clinical assessment team assigned the individual
a ranking from one to four: “excellent” (4), “good” (3), “fair” (2), or “poor” (1) (Lyketsos
et al., 2005). Due to limited numbers of participants falling in the poor and fair ranges,
data were collapsed into the following groups: “poor or fair,” “good,” and “excellent.”
The inter-rater reliability of the GMHR has been examined in a random sample of 150
participants of the Cache County Study and showed good inter-rater reliability, r = .704,
p < .001 (Lyketsos et al., 2005). In a separate sample, the GMHR demonstrated
concurrent validity with number of medical diagnoses and medications as well as
predictive validity in its association with mortality (Lyketsos et al., 1999). The interrater
reliability of the GMHR was also high in this study with a weighted kappa of .93
(Lyketsos et al., 1999).
Other covariates that were tested in statistical models due to potential effects on
both informal costs and antidementia medications included the person with dementia’s
place of residence and gender. With respect to gender, prior research has reported that
males demonstrate greater variability in treatment response to antidementia medications
than females (illar-Fernadez, Bjerrum, Feja, & Rabanaque, 2009). Place of residence may
reflect severity of dementia as persons living in assisted living centers may experience
more NPS and potentially medication use. Place of residence was updated at each visit
and coded based on private home, assisted living, nursing home. The current study
included individuals living in the community and in assisted living centers and excluded
nursing home residents, due to residents in a nursing facilities incurring formal costs, not
informal costs.
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Statistical Analysis
Linear mixed effect models were used to examine the association between
antidementia medications (predictor or independent variable) and the informal costs of
dementia care (outcome or dependent variable). Linear mixed models can accommodate
various characteristics of data that are correlated (multiple measures for each participant),
when the independent variable groups are uneven (antidementia medication use versus no
use), there are an unequal number of measurements for participants, and the
measurements are not taken at fixed time points (Verbeke & Molenberghs, 2000), all
characteristics that are present in DPS. Use of each medication type (antidementia,
psychotropic, anticholinergic) was used as a time varying variable as updates of
medications were obtained at each visit. Additional covariates tested included dementia
severity (time varying CDR), general health (time varying GMHR), gender, and
participant place of residence (time varying). To establish the best final model, model fit
was assessed using -2 log likelihood, comparing more complex models (addition of
covariates sequentially) to less complex models (lacking the covariate). Significance
level for model fit was p < 0.05.
Because cost distributions tend to be highly skewed, a gamma logarithmic link
function was used, which has been previously applied to the DPS data when estimating
costs (Rattinger et al., 2015). The gamma distribution is used for positively skewed data
that does not have negative values (Grover, Sabharwal, & Mittal, 2013). Thus, the
gamma model estimates are exponentiated to facilitate interpretation. For example, a
hypothetical result might be that AD has a beta of approximately .65 compared to the
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reference category of other dementia. Exponentiating this value yields a exp(beta) of 2,
which can be interpreted as AD dementia having twice the cost of other dementias.
Finally, as antidementia medications have different effects according to stages of
dementia severity (Atri, 2011), I restricted the sample to only participants with mild
dementia (CDR global score = 1 or less) at baseline.

Results

Sample Characteristics
A total of 328 participants were identified with dementia from the CCSMA and
enrolled into the DPS. The participants included in the sample only differed significantly
from the excluded participants in the daily informal costs, with the 12 excluded
participant’s minimum cost of $0.01 and maximum cost of $318.13 (Table 2.2). As
statistical models with log-link functions are unable to handle 0, the dollars were
transformed such that $.01 was added to all values prior to analyses. Thus, the actual
range of costs would be $0 and $318.12.
Preliminary analyses showed no significant difference in the use of antidementia
medication between persons with AD compared to those with other dementias (Table
2.3). Thirty-nine participants were excluded from the sample because they resided in a
skilled nursing facility. Of the remaining 289, eight were excluded due to missing
medication data and an additional four persons were excluded due to missing CDR data.
The final number of participants included in the analyses was 277.
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Table 2.2
Baseline Characteristics of Included Versus Excluded in Sample
Included (N = 277)
─────────────────
Characteristics

N

%

M

SD

Excluded (N = 12)
──────────────
N

%

M

SD

2

Fisher’s
exact

Female
147
53.1
5 55.6
.02
Residence
Home
214
77.3
6 66.7
.55
Assisted living
63
22.7
3 33.3
Using antidementia meds
55
19.9
1 25.0
.07
Using psychotropic meds
145
52.3
1 25.0
1.18
Using anticholinergic meds
56
20.2
0
0.0
3.56
+
GMHR health
Fair/poor
51
18.4
2 22.2
.08
Good/excellent
226
81.6
7 77.8
CDR+
Mild
219
79.1
4 100.0
1.86
Moderate/severe
58
20.9
0
0.0
Age at baseline
85.6
5.6
88.1
6.2
Education
13.4
2.8
13.6
2.7
Age at dementia onset
82.2
5.8
84.2
7.6
Dementia duration in years
3.4
1.9
3.9
2.0
Daily cost in Utah
41.8
80.0
111.5 145.2
+ Note these covariates were further collapsed because of low frequency in the CDR and GMHR cells.
* Significant differences between at p < .05.
** Significant differences between at p < .01.

t

1.51
.20
1.13
.97
2.22*

Out of the total sample of participants, 40.5% taking antidementia medication
were also taking psychotropic medication, 18.5% taking antidementia medication were
also taking a level two or three anticholinergic medication, and 36.1% taking
psychotropic medication were also taking a level two or three anticholinergic medication.
For the subsample of 219 participants with mild dementia severity at baseline, 30.7%
were taking antidementia medication throughout the study, 58% were taking
psychotropic medication throughout the study, and 22.6% were taking a level two or
three anticholinergic medication throughout the study. Approximately 26.3% of females
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Table 2.3
Baseline Characteristics of Sample: AD Versus Not AD
AD (N = 199)
─────────────────
Characteristics

n

%

M

SD

Not AD (N = 78)
──────────────
n

%

M

SD

2

Fisher’s
exact

Female
113
56.8
34 43.6
3.92*
Residence
Home
147
73.9
67 85.9
4.61*
Assisted living
52
26.1
11 14.1
Using antidementia meds
45
22.6
10 12.8
3.37
Using psychotropic meds
106
53.3
39 50.0
.24
Using anticholinergic meds
38
19.1
18 23.1
.55
GMHR health+
Fair/poor
29
14.6
22 28.2
6.93**
Good/excellent
170
85.4
56 71.8
CDR+
Mild
155
77.9
64 82.1
.59
Moderate/severe
44
22.1
14 17.9
Age at baseline
86.2
5.7
84.0
4.9
2.98**
Education
13.4
2.9
13.5
2.6
-.19
Age at dementia onset
82.8
5.9
80.7
5.2
2.73**
Dementia duration in years
3.4
1.9
3.3
1.6
.39
Daily cost in Utah
39.5
78.1
47.8 84.9
-.77
+ Note these covariates were further collapsed because of low frequency in the CDR and GMHR cells.
* Significant differences between at p < .05.
** Significant differences between at p < .01.

and 32.9% of males were using antidementia medication at any time throughout the study
compared to 73.7% of females and 67.1% of males never using antidementia medication
throughout the study (2 = 6.01, df = 1, p = .015). For the subsample of 219 participants
with mild dementia severity at baseline, approximately 28% of females and 33% of males
were using antidementia medication at any time throughout the study compared to 72%
of females and 67% of males never using antidementia medication throughout the study
(2 = 2.91, df = 1, p = .096). Figure 2.1 displays the duration of antidementia medication
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Figure 2.1. Participants’ pattern of antidementia medication use over time.
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use of those individuals who were ever on the medication in the whole sample. The yaxis shows the count of participants in each group, (started before baseline, n = 65,
started after baseline, n = 35). For each subject, the dots represent each visit and the lines
represent the time between visits, with green indicating antidementia medication use, red
indicating no antidementia mediation use, and blue indicating unknown antidementia
medication use. For example, the second listed participant that started using antidementia
medication after baseline was not using antidementia medication at the first visit, started
using antidementia mediation at the second visit, discontinued antidementia medication
use at the third visit, used antidementia medication between visits three and four, and
finally did not use antidementia medication for remainder of the study time. The figure
displays a majority of participants who were on antidementia medication at baseline,
continued using it for the duration of the study. The longest a participant was on
antidementia medications was approximately eight years.
Of the participants who ever used antidementia medication, 41.1% progressed to
residing in assisted living compared to 33.7% who never used antidementia medications
(2 = 1.42, df = 1 , p = .233). Participants who ever took antidementia medication were of
similar heath, with 49.5% of poor or fair heath status compared to 54.7% who never used
antidementia medications (2 = .66, df = 1, p = .417). Approximately 76.8% of
participants who ever took antidementia medications progressed to moderate or severe
CDR severity ratings compared to 44.2% who never used antidementia medications (2 =
26.46, df = 1, p < .001).
Overall, the daily informal costs for milder stages of dementia were lower than for

29
severe dementia. Figure 2.2 displays the median daily informal cost by severity of
dementia at baseline: for mild dementia estimated informal cost was $9.92, for moderate
dementia $30.02, and for severe dementia $46.99.
Over time, there was substantial variability in costs for a subset of the sample.
Figure 2.3 displays person specific trajectories of informal costs over time, with the blue
line indicating the moving average or general trend of the data and the shaded grey region
indicating the 95% confidence band. There is higher density of person specific
trajectories near zero informal costs compared to informal costs greater than or equal to
$100. There were 180 participants who had informal costs below $20 at baseline and an
additional 63 participants had informal costs below $100 at baseline.

Association of Antidementia Medications
and Costs
Over time, informal costs did not change significantly (expβ = 1.03, p = .456).

Severity of Dementia

Median

Mild

Mean
SD

Moderate

Severe

0

10

20

30

40

50 60 70 80
Cost in U.S. Dollars

90

Figure 2.2. Bar graph of informal costs by dementia severity at baseline.
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Figure 2.3. Person-specific plot of daily cost over time.

Use of antidementia medications was not significantly associated costs (expβ = .80, p =
.158). With the inclusion of significant covariates, the final model showed use of
antidementia medication was not associated with informal costs (expβ = .79, p = .090). In
examining gender differences, gender was entered as a covariate, and was not significant
(expβ = .74, p = .107); an interaction between gender and antidementia medication use
was also tested and was not significant (expβ = .72, p = .298). Only dementia severity,
measured by CDR-SB, was significantly associated with an increase (18%) in informal
costs (Table 2.4).
When restricting the sample to only include the participants with mild dementia at
baseline (N = 219), use of antidementia medications was associated with 28% reduction
in informal costs (expβ = .72, p = .039). Again, dementia severity, measured by CDR-SB,
was significantly associated with a 21% increase in informal costs (Table 2.4).
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Table 2.4
Mixed Models of Utah 2015 Cost Value
Final model entire sample
(N = 277)
────────────────────────
95% confidence
lower upper

Exp(β)

df

p

< .001

8.92

17.72

11.90

1

< .001

7.86

18.00

.746

.93

1.06

.98

1

.636

.9.1

1.06

1.04

.72

1

.039

.53

.98

1.22

1.21

1

<.001

1.14

1.27

Parameter

Exp(β)

df

p

Intercept

12.57

1

.99

1

.79

1

.090

.60

1.18

1

<.001

1.14

Time (years)
Taking antidementia meds
CDR-SB

Model with baseline mild severity
(N = 219)
───────────────────────
95% confidence
lower upper

Discussion
This project examined the informal costs of dementia care in a communitydwelling, population based sample of persons with dementia. While the results of the
study did not find a statistically significant effect in the overall sample of participants,
results from restricting the sample to only those with mild dementia at baseline found
antidementia medication use was significantly associated with a 28% decrease in
informal costs. These results suggest that antidementia medications are most effective in
reducing the informal costs of care in early dementia and perhaps less so as severity
increases. Fillit and Hill (2005) reviewed the effects of antidementia medications on costs
of dementia care. This review included three RCTs, two of which found total cost savings
associated with antidementia medication use, but the amount of savings differed due to
different study settings (Europe and U.S.) and differences in assumptions of hours spent
caregiving (Fillit & Hill, 2005). Fillit and Hill also found five studies modeling projected
cost savings when using antidementia medication. All studies took place in the U.S. or
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Canada and evaluated ChEIs cost effectiveness (Fillit & Hill, 2005). Two of these studies
evaluated total costs, with results ranging from $73 in savings at two years for a person
with mild AD to $2290 in savings at two years for a person with moderate AD, both of
which 1999 monetary values (Fillit & Hill, 2005). A potential difficulty in comparing
these two studies is that they assessed different ChEIs, donepezil and rivastigmine. The
Fillit and Hill (2005) review yielded three retrospective studies based on claims made to
managed care organizations in the U.S. (e.g., Medicare). These retrospective studies
evaluated total costs of care with donepezil treatment. Results ranged from total cost
savings of $579 to $3,891 at 12 months (monetary values from years 1997 to 1999) (Fillit
& Hill, 2005). This review (Fillit & Hill, 2005) is useful in showing total cost benefits of
using antidementia medications, but does not specifically address potential informal cost
benefits.
Of note, is the small number of participants in this study using antidementia
medications (29.5% of the overall sample). This limited sample may have resulted in
limited power to detect a significant association. Nonetheless, the frequency of
antidementia medication use reported in the DPS is similar to rates reported in a large,
nationally representative sample. Gruber-Baldini, Stuart, Zuckerman, Simoni-Wastila,
and Miller (2007) evaluated a nationally representative sample of 12,697 persons with
dementia from a Medicare database in 2002, which was also the start of the DPS. Results
found that approximately 24.7% of individuals reported using antidementia medications,
which is slightly lower than the usage reported in the DPS sample (Gruber-Baldini et al.,
2007).
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As expected, greater severity of dementia was associated with higher informal
costs. Other studies concur with these findings. For example, Wolstenholme et al. (2002)
followed 100 participants with AD for up to 11 years who were enrolled from clinics in
the UK to assess overall costs of care and disease severity as measured by the MiniMental Status Exam (MMSE) and the Barthel ADL Index. Results found both the MMSE
and Barthel ADL Index were significant predictors of increases in informal costs of care
(Wolstenholme et al., 2002). Rapp et al. (2012) similarly reported that participants with
AD living in a French community had greater informal costs with decreases in cognition,
more problems with completing ADLs, and more NPS (Rapp et al., 2012). Of studies
taking place in the U.S., Zhu et al. (2006a) followed 170 people with AD for up to seven
years in the Predictors Study measuring disease severity with the MMSE and Blessed
Dementia Rating Scale (functional symptoms). Results found that worse cognitive and
functional status led to an increase in use of informal care. Additional results from Zhu et
al. (2008) using 172 individuals who were followed for up to 4 years in the Predictors
Study found that level of dependence was associated with an increase in caregiving time,
which would in turn predict higher informal costs.
Dementia severity has been further assessed with DPS data by Rattinger et al.
(2015). Results found informal costs increased with dementia severity, approximately
18% per year after onset and 5% to 8% per year when holding baseline severity constant
(Rattinger et al., 2015). Additionally, Rattinger et al. (2016) evaluated 217 DPS dyads for
cost differences based on the closeness of the caregiver and care-recipient relationship.
Results found that higher relationship closeness was associated with 24% lower informal
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costs (Rattinger et al., 2016). These studies demonstrate important findings within this
dataset, as well as, contributions to modifiers of informal costs.
The current study is significant because there is no known research on the
longitudinal effect of antidementia medication specifically on informal costs. A main
strength of the current study is that it is population-based and longitudinal, which may
make the results more generalizable to persons with dementia living in the community.
Another advantage of this study is DPS had high participation rates (85% initial
enrollment) and high ongoing participation rates at follow-up (95-100% excluding
nonparticipation due to death). Another advantage of this study is that the method used to
calculate informal cost allowed for cost estimates to be generalized throughout Utah.
A potential limitation of this study is related to using all forms of dementia instead
of specifically using AD or VaD. Using heterogeneous forms of dementia may influence
how effective antidementia medications are on symptoms, and certain forms of dementia
also may require more or less informal care than others. The rates of antidementia use can
differ between types of dementia (e.g., Table 2.2), although the frequency of use did not
differ in this sample. Additionally, individual antidementia medication types were not
examined due to low frequency of use. Finally, the homogeneous population of Cache
County, including being White and the majority of individuals being members of The
Church of Jesus Christ of Latter-day Saints (LDS), may limit generalizability. These
factors can influence the participants’ or caregivers’ behaviors, for example, family time
and relationships are valued and emphasized in this religion, which may have affected
amount of time-spent caregiving or amount of time reported caregiving.
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Future studies may evaluate other factors that may contribute to the cost of
informal dementia care, particularly factors that can be targeted for change. For example,
much of the literature points to dementia severity affecting informal costs, but current
treatments do not allow for much change in dementia severity. Further research should
find ways to improve dementia severity, particularly with cognitive and functional status
(Rapp et al., 2012; Wolstenholme et al., 2002; Zhu et al., 2006a) or the use of devices to
promote functioning, such as electronic reminding or monitoring devices (Riikonen,
Makela, & Perala, 2010). Other factors have also been associated with lower informal
costs, including caregiver relationship closeness to the care-recipient (Rattinger et al.,
2016). Caregiver closeness is a modifiable factor that has impact on informal cost, but
further research is needed to examine aspects of the “closer” relationships and how these
relationships translate to the use of environmental supports and care-related behaviors. In
summary, the results of this study did not find that antidementia medications reduced the
costs of informal dementia care in a population-based sample, but that there are several
identified avenues for future research.
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CHAPTER 3
STUDY 2: NEUROPSYCHIATRIC SYMPTOMS AND
ANTIDEMENTIA MEDICATIONS

Abstract
Pharmacological treatments for dementia include cholinesterase inhibitors and Nmethyl-D-aspartate receptor antagonists (antidementia medications). These antidementia
medications are associated with a delay in the progression of the cognitive and functional
symptoms, but studies of the effects of antidementia medications on neuropsychological
symptoms (NPS) show varying results. This project used extant data from the
longitudinal, population-based Cache County Study on Memory and Aging (CCSMA)
and the Dementia Progression Study (DPS), which included permanent residents aged ≥
65 of Cache County, Utah. Medication use was based on inspection of each participant’s
medications and interview; NPS were estimated using the Neuropsychiatric Inventory
(NPI). Linear mixed models were used to assess the association between antidementia
medications and NPS. Results indicated that use of antidementia medications was
associated with a 28% increase in NPS (expβ = 1.28, p < .001). However, this association
was no longer significant with the inclusion of covariates, specifically, the use of
psychotropic medications. Use of any psychotropic medication was significantly
associated with a 30% increase in NPI score. Overall, antidementia medication use may
not significantly reduce NPS, but the use of antidementia medications may reflect
patterns of use that are prompted by severity of dementia and NPS.
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Introduction
Tacrine was the first cholinesterase inhibitor (ChEI) approved by the U.S. Food
and Drug Administration (FDA) in 1993, but due to adverse side effects (hepatotoxicity),
it is no longer on the market (Atri, 2011). Since then, several other antidementia
medications have received FDA-approval including the ChEIs donepezil (Aricept),
galantamine (Razadyne), rivastigmine (Exelon), and the N-methyl-D-aspartate (NMDA)
receptor antagonist, memantine (Namenda; Atri, 2011). There has not been substantial
evidence to show superior efficacy of one ChEI over another (Atri, 2011). To date,
studies have shown ChEIs are more effective in treating mild AD, while combination
treatment (ChEI + NMDA) is beneficial over monotherapy (ChEI or NMDA alone) in
moderate to severe stages of AD (Atri, 2011).
A recent literature review studied antidementia medication efficacy in both shortterm randomized control trials (RCT) and long-term observational studies (LTOS). It
found that in short-term RCT’s, ranging from six months to one year, antidementia
medications improved or decreased the rate of cognitive decline among persons with AD,
while the LTOS studies found the persistence of medication use reduced cognitive,
functional, and global decline among persons with AD (Rountree et al., 2013). The
results from LTOC studies also showed that combination therapy (ChEI and memantine)
was superior to ChEI monotherapy across the spectrum of severity in AD (Rountree et
al., 2013). These results show that antidementia medications can be advantageous to the
progression of cognitive and functional decline in dementia in the short and long term.
It is less clear, however, if antidementia medications are also effective in
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decreasing the occurrence of neuropsychiatric symptoms (NPS). NPS are common over
the course of dementia (Cummings, 1997; Tschanz et al., 2011) and often stressful and
burdensome to caregivers (Rymer et al., 2002). A number of studies have examined the
effects of antidementia medications on NPS, the results of which have been summarized
in reviews and meta-analyses. Grimmer and Kurz (2006) conducted a systematic review
of studies examining antidementia medications and NPS, with the average duration of
these studies being 20 weeks and ranging from 6 to 52 weeks. In their review, only two
out of the 14 studies (six tacrine, six donepezil, and two galantamine) found statistical
significance of antidementia medications reducing NPS in the treatment group over the
placebo group (Grimmer & Kurz, 2006). Additionally, in nine of the 14 studies,
psychotropic medications were also being used by 36-62% of individuals, making it
difficult to infer whether any beneficial effects were attributable to antidementia
medications or psychotropic medications (Grimmer & Kurz, 2006). A more recent
systematic review by Rodda et al. (2009) of 14 randomized, placebo-controlled trials
(nine donepezil, three galantamine, and two rivastigmine) reported that three of the
studies found a decrease in NPS. The median length of these studies was 24 weeks
(ranging from 12 to 170 weeks), which is a similar length to studies covered in previous
reviews (Rodda et al., 2009). One limitation noted in the Rodda et al. review was that
many of the studies were not specifically designed or had enough power to detect
changes in NPS. Some of the studies included also had a short duration of treatment,
which could impact the efficacy of antidementia medication effects. Another limitation,
similar to that reported in other reviews (Grimmer & Kurz, 2006), is that many studies
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reported high rates of psychotropic medication use in the participants for which there was
no statistical control. One strength of the review was its inclusion of studies that did not
allow participants to use medications with cholinomimetic or anticholinergic effects
which can decrease the effectiveness of antidementia medications (Rodda et al., 2009).
Antidementia medications may differentially affect NPS. In their review,
Cummings and colleagues identified that eight of 15 AD clinical trials found differences
in antidementia mediations affecting NPS, with the studies having a median duration of
six months and ranging from three months to two years (Cummings et al., 2008). Reports
found positive outcomes, with mood symptoms and apathy responding better to ChEIs
and irritability and agitation responding better to memantine (Cummings et al., 2008).
Eight studies that found ChEIs or memantine to significantly decrease NPS allowed
participants to be taking psychotropic medication, with the one other study not indicating
whether psychotropic medication was allowed (Cummings et al., 2008). The use of
psychotropic medications may have confounded these results as both types of
medications can affect NPS. Studies, within this review, reporting non-significant results
on NPS were more likely to involve institutionalized individuals who had few behavioral
disturbances at baseline, which may have affected the ability of staff to identify
behavioral changes at milder levels of severity (Cummings et al., 2008). As noted by the
authors, one limitation of some of the studies was the substantial variability of severity
levels of patients in the trials, with the majority of studies including individuals with
severe dementia.
The importance of controlling for psychotropic medications in analyses
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examining the association of antidementia medications and NPS is underscored by
prescription patterns of psychotropic medications as reported in a Swedish study by
Gustafsson, Sandman, Karlsson, Gustafson, and Lovheim (2013). This study, which
enrolled 2,019 institutionalized individuals with cognitive impairment, found significant
associations between psychotropic drug use and specific NPS. Gustafsson et al. found
that antipsychotic medication use was associated with aggressive behavior, verbally
disruptive behavior, passivity, hallucinations, and disorientation; anxiolytic drug use was
associated with verbally disruptive, restlessness, inappropriate behaviors, and depressive
symptoms; hypnotic and sedative medication use was associated with verbally disruptive
and inappropriate behaviors; and antidepressant medication use was associated with
verbally disruptive and depressive symptoms (Gustafsson et al., 2013). Gustafsson et al.
demonstrated how psychotropic medications contribute to a decrease in NPS, but also
how different NPS are more likely to have certain psychotropic medications prescribed.
While previous reviews (Grimmer & Kurz, 2006) reported that antidementia
medications may improve NPS (at least in a few studies), still there were inconsistencies
across studies with several showing no effect. Advantages of the RCTs discussed in these
reviews include the randomization of treatment and control groups and control for
participant characteristics, while limitations include short duration of study, participants
frequently having severe dementia, and that many of the studies being conducted in
institutional settings.
Given the uncertain efficacy of antidementia medications on NPS in dementia, the
current project examined whether antidementia medications decreased NPS in dementia
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in a population-based sample from the Cache County Study on Memory in Aging
(CCSMA). There are several advantages of this population-based study including followup of incident (newly identified) persons with dementia, and up to 10 years of follow-up.
I examined whether persons with dementia taking antidementia medications would
exhibit less severe neuropsychiatric symptoms than those who were not taking
antidementia medications while controlling for psychotropic and anticholinergic
medications. The latter was examined as these medications may enhance symptoms of
dementia (e.g., cognitive impairment; Carriere et al., 2009).

Methods

Sample
This project used extant data from the Cache County Study on Memory in Aging
(CCSMA; 1995-2007) and the ancillary study, the Dementia Progression Study (DPS;
2002-2013). The sample of persons with dementia was identified from the longitudinal,
population-based CCSMA, which included permanent residents aged ≥ 65 of Cache
County, Utah. The CCSMA examined the prevalence, incidence, and risk factors of
dementia in this U.S. county, which has been recognized for its residents’ longevity. In
Wave 1, CCSMA enrolled 5,092 (89.7%) of the eligible individuals in the county
(Breitner et al., 1999) and subsequently conducted three additional triennial waves of
dementia screening and evaluation described briefly below.
According to Breitner et al. (1999), the participants were given the 100-point
Modified Mini-Mental State Examination (3MS) cognitive screener in the first stage.
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Some of the participants (386) received a proxy interview if they could not complete the
3MS, scored below a 15 on the orientation subset of the 3MS, scored below 60 on the
3MS, or if the individual was otherwise deemed unreliable by the interviewer (Breitner et
al., 1999). If an individual’s 3MS score was below 87 or if he/she was a member of a
designated subsample to complete all evaluation stages, a knowledgeable informant
completed a dementia questionnaire (DQ) with a technician. The DQ is a 50-item semistructured interview of the symptoms of dementia and general medical history, the results
of which were then rated for degree of cognitive impairment by a neuropsychologist and
geriatric psychiatrist. Individuals with ratings of “questionable” or “probable” dementia
(Wave 1) or “moderate impairment,” “questionable,” or “probable” dementia (Wave 2)
were asked to undergo a clinical assessment, which was conducted by a research nurse
and psychometrist. In the clinical assessment, the research nurse interviewed an
informant about the participant’s medical history and current medications, and the
participant underwent a physical examination including assessment of blood pressure and
a standardized neurological examination. The psychometrist administered a battery of
neuropsychological tests to the participant (Tschanz et al., 2000). Additionally, the
knowledgeable informant completed the NPI.
A neuropsychologist, geriatric psychiatrist, examining nurse, and psychometrist
reviewed the clinical assessment results. A preliminary diagnosis of dementia was given
if meeting the criteria from the Diagnostic and Statistical Manual-III-R (DSM-III-R;
APA, 1987). Individuals, who received a classification of dementia or “mild/ambiguous”
(prodromal AD), were sent for follow-up laboratory testing and neuroimaging (complete
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blood counts, routine chemistries, serum B-12, folate, thyroid function test, urinalysis,
and Magnetic Resonance Imagining (MRI) or Computed Tomography (CT) scan).
Persons with suspected dementia were examined at their place of residence by a geriatric
psychiatrist who repeated the neurologic examination, Mini-Mental State Exam (MMSE),
and clinical history. After a review of all available clinical exams, a panel of expert
clinicians consisting of geriatric psychiatrists, a neurologist, neuropsychologists, and a
cognitive neuroscientist assigned a final diagnosis (Breitner et al., 1999). A diagnosis of
AD was given according to the National Institute of Neurological and Communicative
Diseases and Stroke-Alzheimer’s Disease and Related Disorders Association (NINCDSADRDA; McKhann et al., 1984). A Vascular Dementia (VaD) diagnosis was given based
on the National Institute of Neurological Disorders and Stroke-Association Internationale
pour la Recherche et l’Enseignement en Neurosciences (NINDS-AIREN) criteria
(McKhann et al., 1984). Diagnoses of other dementias followed standard research
criteria. Additionally, age of dementia onset (age at which the individual met DSM-III-R
criteria for dementia), severity of dementia using the Clinical Dementia Rating (CDR;
Hughes et al., 1982), and rating of overall health with the General Medical Health Rating
(GMHR; Lyketsos et al. (2005) were assigned. Persons with dementia completed a
clinical assessment 18 months later to clarify the diagnosis (Breitner et al., 1999).
The CCSMA identified 942 cases of dementia from the four waves of dementia
ascertainment conducted in 1995, 1998, 2002, and 2005. Each of the waves consisted of a
similar protocol described above with the exception of modified cut-off points on the
3MS and dementia questionnaire (DQ), and with Waves 3 and 4 excluding the DQ stage.
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From 2002 to 2007, the individuals who were identified with incident dementia in
the CCSMA were invited to enroll in the Dementia Progression Study (DPS; Tschanz et
al., 2011). The DPS was a longitudinal study running from 2002 to 2013 and examined
factors that affect the rate of dementia progression in persons with AD and other
dementias. A research nurse and psychometrist conducted in-home evaluations to the
participants and their caregivers approximately every 6 to 8 months. The in-home
evaluations consisted of a 45- to 60-minute neuropsychological test battery, brief
neurological and physical examination, assessment of functional abilities using the CDR
and Dementia Severity Rating Scale (DSRS; Clark & Ewbank, 1996), interview of health
and psychiatric conditions, medication review and assessment of the caregiver’s wellbeing and time spent providing care (Tschanz et al., 2011). The current project used the
data obtained from both the CCSMA and DPS in examining the effects of antidementia
medications on NPS in dementia.

Procedures
For this research question, all persons with dementia identified from the CCSMA
& DPS were considered for analyses (N = 942), which included both prevalent and
incident cases. Because of potential differences between prevalent and incident cases,
subjects were coded as either having been identified as a prevalent or incident case and
differences between these two groups were examined.
Independent/predictor variables. All medication use, including antidementia
medications, was recorded by the research nurse who inspected all the medications taken
by the individual with dementia at the diagnosis visit of the CCSMA, as well as all
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follow-up visits of the DPS. Because information on medication usage between visits was
not available, medications used at consecutive visits was assumed to be taken throughout
the time between visits. Medication use was confirmed with visual inspection of the vials
(Medical Record, see Appendix A) and for persons living in nursing homes, confirmed
with a Medication Administration Record, with the following methods described
previously (Zandi, 2005). Medications were reviewed and coded using the Mosby Drug
Reference System (Skidmore-Roth, 2009). Subjects were classified according to use (or
no use) of antidementia medications (CHEIs or NMDA receptor antagonists).
Medications tested as covariates included: any psychotropic medications (antipsychotic,
antidepressant, and anxiolytic/sedative-hypnotic, or mood stabilizing medications), as
well as medications with anticholinergic effects. Anticholinergic medications were
included as a covariate because of potential adverse effects on cognition (Carriere et al.,
2009). Anticholinergic medications were classified using The Anticholinergic Cognitive
Burden Scale (ACBS, see Appendix B), which is a list of anticholinergic medications
ranked from one to three with level one meaning possible anticholinergic and levels two
and three indicating definite anticholinergic properties (Campbell et al., 2010). Any
medications classified, as an anticholinergic at a level two or three were entered as a
covariate.
The other covariates that were tested include gender, place of residence
(community, assisted living, and nursing home), dementia duration, dementia severity,
and overall health. With respect to including gender, residence, and dementia duration as
covariates, the literature supports a potential need to examine their effects. For example,
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gender effects have been shown in prior research, with males demonstrating greater
variability in treatment response to antidementia medications than females (illar-Fernadez
et al., 2009). Place of residence may reflect severity of dementia and therefore NPS and
medication use, with more severely impaired individuals likely living in institutionalized
settings. Place of residence was updated at each visit and coded based on private home,
assisted living, nursing home. Since dementia was identified at varying times post-onset,
duration of dementia was entered as a covariate in statistical models.
The CDR (see Appendix C) is a rating based on a semi-structured interview
administered to the caregiver and participant and estimates the severity of cognitive and
functional impairments across six domains: memory, orientation, judgment and problem
solving, community affairs, home and hobbies, and personal care (Hughes et al., 1982).
The CDR global scoring method was used with a scale ranging from 0 = no impairment,
0.5 = questionable impairment, 1 = mild impairment 2 = moderate impairment, 3 = severe
impairment, 4 = profound impairment, and 5 = terminal (Hughes et al., 1982). Due to
limited numbers of participants falling in the mild and severe ranges, data were collapsed
into 0, .5, 1 = mild impairment, 2 = moderate impairment, 3, 4, 5 = severe impairment.
The CDR has moderate to high inter-rater reliability with a kappa = 0.62 (Rockwood et
al., 2000).
Overall health status was also used as a covariate, and assessed using the General
Medical Health Rating (GMHR, see Appendix D), which provides a global rating of an
individual’s health. The rating is based on information obtained at each visit from the
medical interviews conducted by the research nurse, a review of medications and brief
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physical and neurological exams (Lyketsos et al., 2005). In assigning the ratings,
consideration is given to the number of conditions, acute or chronic status, and whether
the conditions are controlled by treatments (Lyketsos et al., 2005). Based on this
information, a geriatric psychiatrist and clinical assessment team assigned the individual
a ranking from one to four: “excellent” (4), “good” (3), “fair” (2), or “poor” (1) (Lyketsos
et al., 2005). The interrater reliability of the GMHR has been examined in a random
sample of 150 participants of the Cache County Study and showed good inter-rater
reliability, r = .704, p < .001 (Lyketsos et al., 2005). In other samples, the GMHR has
demonstrated concurrent validity with number of medical diagnoses and medications as
well as predictive validity in its association with mortality (Lyketsos et al., 1999). The
inter-rater reliability of the GMHR in a separate sample was high in this study with a
weighted kappa of .93 (Lyketsos et al., 1999).
Outcome variable. The Neuropsychiatric Inventory (NPI, see Appendix E) was
used to measure the type and severity of NPS, usually present in dementia (Cummings et
al., 1994). The NPI-10 item version was used to assess NPS over the past month
including delusions, hallucinations, agitation, dysphoria, anxiety, apathy, irritability,
euphoria, disinhibition, and aberrant motor behavior (Cummings, 1997). The NPI was
completed by a knowledgeable informant in the CCSMA or the caregiver in the DPS and
was completed at each clinical assessment. The administration of the NPI consisted of a
structured interview assessing whether the symptoms occurred. If a symptom was
endorsed, the caregiver was asked to rate the frequency (4-point scale) and severity (3point scale) of the symptoms. The outcome variable was total NPI score, which was
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calculated by summing the product of the frequency and severity scores across the
domains.
Content validity of the NPI items was assessed by a group of 10 international
experts in the field (geriatric psychiatry, behavioral neurology, and neuropsychology)
who rated the screening questions as 1 = well assessed to 4 = poorly assessed, with each
category besides aberrant motor behavior having a rating of less than 2 (Cummings,
1997). Concurrent validity of the NPI was tested with the Behavioral Pathology in
Alzheimer’s Disease (BEHAVE-AD) and Hamilton Rating Scale for Depression, with
results showing no statistically significant differences between these assessments
(Cummings, 1997). Convergent validity with the Apathy Evaluation Scale (apathy), Brief
Psychiatric Rating Scale (delusions and hallucinations), Cohen-Mansfield Agitation
Index (agitation), Cornell Scale for Depression in Dementia (depression) was moderate to
strong in the four domains with depression having the strongest correlation, r = .61 and
apathy having the weakest correlation, r = .31 (de Medeiros et al., 2010). The interrater
reliability for each item was overall moderate to strong ranging from ICC = .50-.97 (de
Medeiros et al., 2010). The NPI test-retest reliability was assessed over a 3-week time
span and showed significant correlation with .79 for frequency and .86 for severity
(Cummings, 1997).

Statistical Analysis
Linear mixed effect models were used to examine the association between
antidementia medications (independent variable) and NPS (dependent variable).
Antidementia medications were used as a time varying variable, as updates of
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medications were acquired at each visit. First overall psychotropic medications were
assessed as a covariate, then additional analyses evaluated the separate classes of
psychotropic medication (antidepressants, antipsychotic, etc.) because research found that
certain psychotropic medications may affect NPS differently (Rosenberg et al., 2012).
In general, mixed models are recommended when the groups of participants are
uneven, there are an unequal number of measurements for participants, and the
measurements are not taken at fixed time points (Verbeke & Molenberghs, 2000), which
are conditions present in the CCSMA and DPS. To establish the best final model, model
fit was assessed using -2 log likelihood, comparing more complex models (addition of
covariates sequentially) to less complex models (lacking the covariate). Significance
level for model fit was p < 0.05.
Due to the residuals of the NPI being positively skewed and the distribution of the
NPI departing substantially from normal, the NPI total score was transformed by taking
the natural log of the score. To account for scores of 0, a value of 1 was added to all
scores as the natural log of 0 is undefined. This transformation produced a new
distribution that more closely approximated a normal distribution. Appendix F shows NPI
scores for each visit and Appendix G shows the natural log of NPI for each visit.
UCLA Institute for Digital Research and Education explains that to facilitate
interpretation of the mixed models, natural log estimates are exponentiated (Institute for
Digital Research and Education [IDRE], 2016). For example, a hypothetical result might
be that females have a beta of approximately .11 compared to the reference category of
males. The predicted probability is achieved by exponentiating the beta value. The
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exp(.11) is 1.12, which can be interpreted as females having 12% more severe NPS than
males (IDRE, 2016).

Results

Sample Characteristics
In the CCSMA, 942 participants were diagnosed with dementia, either in the
prevalence or incidence waves. Of these, 11 had no measures from the clinical
assessment and were diagnosed from review of medical records and/or autopsy results,
leaving 931 available for analyses. The percentage of participants taking antidementia
medications in the prevalent versus incident waves differed significantly at baseline (2 =
19.86, df = 1, p < .001) with only 1.4% of prevalent cases using antidementia medications
compared to 8.6% of incident cases using antidementia medications (Table 3.1). There
were 10 participants with missing values for medications across prevalent or incident
Table 3.1
Baseline Number of Participants Using Antidementia Medications by Prevalent and
Incident Cases and Dementia Type

Dementia categories
Prevalent dementia
Incident dementia

Using antidementia
medication
────────────
n
%
5
1.4
49
8.6

Not using antidementia
medication
────────────
n
%
343
98.6
524
91.4

2

19.86**
Incident AD
Incident other dementia

39
10

10.0
5.5

352
172

90.0
94.5
3.19

* Significant differences between at p < .05.
** Significant differences between at p < .01.
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cases. Given the infrequent use of antidementia medications in prevalent cases, only
incident dementia cases were used in the current analysis. An examination of incident
dementia type by antidementia medication use revealed a somewhat higher percentage of
participants with AD were taking antidementia medications (10%) than those with other
dementia (5.5%); however this difference was not statistically significant (2 = 3.19, df =
1, p =. 079). Thus, participants with any form of dementia were included in the analyses,
but dementia type was tested as a covariate. Finally, the sample was further restricted to
include those not missing data from the NPI (eight cases) and CDR (three cases) and
antidementia medication usage (two cases) resulting in a final sample consisting of 569
cases of incident dementia.
In examining differences between participants included versus excluded in the
analysis, those excluded were rated with more severe dementia, with 44.4% of moderate
or severe dementia at baseline and only 17.4% of participants included in the analysis of
moderate or severe dementia at baseline (Table 3.2).
Table 3.3 shows the baseline characteristics of cases with incident AD compared
to incident other dementias. Participants with other dementias were slightly younger
compared to those with AD (t = 3.03, df = 567, p =. 003) and the mean age of dementia
onset at baseline was slightly older in persons with AD compared to those with other
dementia (t = 3.15, df = 567, p =. 002). There were significantly more females with AD
(64.4%) compared to other dementias (51.9%). Persons with AD had significantly better
health, with 63.7% rated as good or excellent health compared to 36.5% of persons with
other dementia rated as good or excellent health at baseline.
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Table 3.2
Baseline Characteristics of Sample: Included in Analysis Versus Excluded

Characteristics
Female
Dementia type
AD
Other
Residence
Home
Assisted living
Nursing facility
Antidementia medication use
Psychotropic medication use
Anticholinergic medication use
Health status+
Poor/fair
Good/excellent
CDR+
Mild
Moderate/severe
Age at baseline
Education
Age at dementia onset
Dementia duration in years
Total NPI score

AD (N = 199)
─────────────────
n
%
M
SD

Not AD (N = 78)
──────────────
n
%
M
SD

344

60.5

7

53.8

388
181

68.2
31.8

7
6

53.8
46.2

1.20

451
58
60
49
223
101

79.3
10.2
10.5
8.7
39.5
17.9

10
1
1
0
2
2

83.3
8.3
8.3
0
22.2
22.2

.12

256
313

45.0
55.0

2
10

16.7
83.3

3.82

465
98

82.6
17.4

5
4

55.5
44.4

4.42**

85.2
13.3
83.5
1.7
4.9

6.1
3.0
6.3
1.3
9.2

2
.23

Fisher’s
exact

t

1.62
1.11
.11

86.5
13.4
85.2
1.3
3.4

6.6
3.3
6.5
1.1
5.0

-.78
-.15
-1.01
1.21
.37

+ Note these covariates were further collapsed because of low frequency in the CDR and GMHR cells.
* Significant differences between at p < .05.
** Significant differences between at p < .01.

NPI scores were highly variable over time. Figure 3.1 displays person-specific
trajectories of total (raw, untransformed) NPI scores, with the bold line indicating the
moving average or general trend of the data. When considered across the entire sample, it
appeared that NPI scores slightly increased and then plateaued over time. The shaded
grey region is the 95% confidence band. There is higher density of person specific
trajectories with an NPI score near zero for measures obtained closer to baseline, with
250 participants having a score of 0 at baseline.
Out of the participants taking antidementia medication (20.8% of the total
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Table 3.3
Baseline Characteristics of Sample: Incidence AD Versus Incidence Other Dementia
AD (N = 199)
────────────────
n
%
M
SD

Not AD (N = 78)
──────────────
n
%
M
SD

Characteristics
2
Female
250
64.4
94 51.9
8.07**
Residence
Home
312
80.4
139 76.8
7.88*
Assisted living
44
11.3
14
7.7
Nursing facility
32
8.2
28 15.5
+
Health status
Poor/fair
141
36.3
115 63.5
36.88**
Good/excellent
247
63.7
66 36.5
CDR+
Mild
319 83.54
146 80.7
.69
Moderate/severe
63
16.5
35 19.3
Antidementia medication use
39
10.1
10
5.6
3.18
Psychotropic medication use
144
37.4
79 44.1
2.32
Anticholinergic medication use
62
16.1
39 21.8
2.69
Age at baseline
85.7
6.1
84.1
6.1
Education
13.3
3.1
13.3
3.0
Age at dementia onset
84.0
6.2
82.2
6.2
Dementia duration in years
1.7
1.3
1.8
1.4
Total NPI score
4.4
8.9
6.0
9.8
+ Note these covariates were further collapsed because of low frequency in the CDR and GMHR cells.
* Significant differences between at p < .05.
** Significant differences between at p < .01.

t

3.03**
-.03
-.91
3.15**
-1.91

sample), 100% were also taking psychotropic medication and 26.9% were taking a level
two or three anticholinergic medication. Figure 3.2 displays the duration of antidementia
medication use of those individuals who were ever on the medications. The y-axis shows
the count of participants in each group. For each subject, the dots represent each visit and
the line represents the time between visits, with green indicating antidementia medication
use, red indicating no antidementia mediation use, and blue indicating unknown
antidementia medication use. The figure shows that a majority of participants who were
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Figure 3.1. Person-specific plot of individual NPI scores over time.

on antidementia medication at baseline, continued using it for the duration of the study.
Of the participants who ever used antidementia medication, 52.9% progressed to
residing in assisted living or nursing facility compared to 40.9% who never used
antidementia medications (2 = 5.54, df = 1 , p = .019). Participants who ever took
antidementia medication were of similar heath, with 60.5% of poor or fair heath status
compared to 62.2% who never used antidementia medications (2 = .12, df = 1, p = .728).
Approximately 89.1% of participants who ever took antidementia medications progressed
to moderate or severe CDR severity ratings compared to 84.7% who never used
antidementia medications (2 = 1.45, df = 1, p = .229).
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Figure 3.2. Participants’ duration of antidementia medication use.
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Association Between Antidementia
Medications and NPS
Model building proceeded sequentially, adding variables one at a time. Except for
the variable of interest, antidementia medications, covariates were retained if they
enhanced the model fit. NPS significantly changed over time, with a 1-year increase in
time indicating approximately 28% increase on the NPI (expβ = 1.28, p < .001). Use of
antidementia medications was significantly associated with NPI such that using these
medications had a 27% increase in NPI score (expβ = 1.27, p = .001). However, once use
of psychotropic medication was included in the model, antidementia medications use was
no longer significant. Retaining only significant terms that produced the most
parsimonious model, the “final” model consisted of CDR, place of residence, dementia
type, antidementia medications (though nonsignificant, retained as the variable of
interest), and psychotropic medications (Table 3.4). Dementia duration was not added to
the final model because it was highly correlated with CDR at r = .342, p < .001. CDR
was chosen because it was more significantly correlated with NPI than dementia
duration. Use of psychotropic medication was associated with a 30% increase in NPI
score. Compared with mild dementia, moderate dementia was associated with
approximately a 50% increase in total NPI and severe dementia with a 60% increase in
total NPI. Participants residing in assisted living (compared to home) had approximately
40% increase in total NPI. Participants with AD had 18% less severe NPI score than
those with other dementias.
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In more granular analyses, I broke down the combined psychotropic medications
into separate drug classes of antidepressants, antipsychotics, sedative/hypnotic/
anxiolytics, and mood stabilizers/lithium medications. Out of the total sample at any
time, 35.5% were on antidepressants, 10.1% were on antipsychotic, 11.9% were on
sedative/hypnotic/anxiolytics, and .3% were on mood stabilizers/lithium medications. In
the statistical model examining antidementia medications and informal care costs, entry
of use of each psychotropic dug class revealed significant covariates for antidepressants
and antipsychotic medications only (Table 3.4). In this model, use of antidementia
medications was significantly associated with NPI such that using these medications had
an approximately a 30% increase in NPI score (expβ = 1.27, p = .001). Of the specific
drug classes, antidepressant medications were significantly associated with a 26%
increase in NPI and antipsychotic medications were significantly associated with a 20%
increase in NPI.

Discussion
In this study of persons with all cause dementia, as with previous work in persons
with AD (Tschanz et al., 2011), NPS was found to increase in severity over time. The use
of antidementia medication was significantly associated with the severity of NPS, but this
association was confounded by use of psychotropic medications. Of those participants
who were taking antidementia medications, 100% of participants were also taking a
psychotropic medication. With respect to the direction of effect, where use of
antidementia medications or psychotropic medications predicted worse NPS, it is likely
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that both served as a marker of more severe dementia or neuropsychiatric symptoms that
prompted participants and caregivers to seek treatment. The more specific model that
separated the psychotropic drug classes yielded similar results as the overall psychotropic
drug use in that use of antidementia, antidepressant, and antipsychotic medications may
in this sample, reflect more severe dementia that prompted caregivers to seek more
aggressive treatment. Rosenberg et al. (2012), provided an in-depth analysis on
psychotropic medication use within this same sample, although restricting the sample to
persons with AD only. That study found that the use of psychotropic medications was
associated with worse NPS score, in particular, SSRIs and antipsychotic medications
(Rosenberg et al., 2012). The authors suggested that the use of psychotropic medications
could reflect severity of symptoms, or a less likely interpretation that these medications
may also increase NPS. The potential effects of psychotropic medications (or
antidementia medications) cannot be teased out within the scope of this observational
study. While previously mentioned reviews (Grimmer & Kurz, 2006; Rodda et al., 2009)
found that antidementia medications may improve NPS, the current study was not able to
support these findings. Some of the studies discussed in the reviews did not find a
beneficial effect of antidementia medications on NPS. The majority of the studies
reporting a positive treatment effect of antidementia medications on NPS were RCTs, but
many were of a short duration (ranging from 42 days to one year), did not account for
psychotropic medication use, and restricted antidementia medication use to a specific
ChEI and/or NMDA receptor antagonist.
Additional longitudinal studies have compared type of antidementia medication
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used and effects on NPS. Cumbo (2005) examined 101 participants with mild to
moderate AD in a randomized 18-month clinical trial examining the effects of
rivastigmine, galantamine, and donepezil on NPS. Participants treated with rivastigmine
had less severe and fewer NPS compared to those treated with donepezil; there were no
significant differences in NPS between those treated with rivastigmine versus
galantamine, or those treated with donepezil versus galantamine (Cumbo, 2005). More
recently, Cumbo and Ligori (2014) compared 177 participants with AD in a 12-month
RCT with the treatment of memantine, donepezil, rivastigmine, or galantamine.
Statistically significant differences in NPS were found between baseline and 12-month
follow-up for the participants treated with memantine, donepezil, or rivastigmine (Cumbo
& Ligori, 2014). The percentage of improved NPI total scores for memantine was 41.6%,
donepezil 38.1%, and rivastigmine 41.3%, compared to only a 31.7% improvement in
total NPI score when participants were on galantamine (Cumbo & Ligori, 2014). Cumbo
(2005) and Cumbo and Ligori (2014) provided important information about longer-term
effects of ChEIs and NMDA receptor antagonist on NPS, though the studies did not
address the issue of comorbid use of psychotropic medications. Specific type of
antidementia medications were not examined in the current study due to limited sample
size.
Like numerous other studies, the current analyses found NPS associated with
dementia severity. Thus, Stella, Laks, Govone, de Medeiros, and Forlenza (2016)
evaluated 156 Brazilian AD patients and found that certain NPS were correlated with
dementia progression, including apathy (.74), agitation (.72), psychosis (.59), affective
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symptoms (.45), and sleep disturbances (.45). Zahodne, Ornstein, Cosentino, Devanand,
and Stern (2015) found in the Predictors Study, a U.S. longitudinal study of AD, and
found that psychosis, depression, and agitation were associated with cognitive decline. So
as in the case of the current study, dementia severity was associated with worse NPS.
A significant strength of the current study is the high participation rate over the
course of CCSMA and DPS. CCSMA with 90% initial enrollment and DPS with 85%
initial enrollment, not only had high turnout of participants but also very high ongoing
participation rates at follow-up (e.g., DPS of 95-100% excluding nonparticipation due to
death). Another advantage of this study was it being population-based, which may make
it more generalizable to persons with dementia living in the community.
This current study is particularly important because there is very limited research
on antidementia medications on NPS with long follow-up times. Although the numbers
of persons on antidementia medications was somewhat low (e.g., 20.8%), it is similar to
the 24.7% reported in a nationally representative sample of 12,697 persons with dementia
from a Medicare database (Gruber-Baldini et al., 2007). However, a more recent crosssectional study of Medicare data from 2008 evaluated medication usage in 52,754
persons with dementia (Rattinger et al., 2013). This study found that approximately
57.1% used antidementia medications over the course of the year. Annual usage of other
medications covered by Medicare Part D in this sample was as follows: use
of antidepressants of 56.4%, use of antipsychotics of 34.0%, and use of a mood stabilizer
of 8.8%. The Rattinger et al. study showed higher usage of all the psychotropic drug
classes compared to the medication usage in the current study and may suggest a trend of
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increasing usage of antidementia medications, as well as, psychotropic medications over
time. Both Gruber-Baldini et al. and Rattinger et al. studies were cross-sectional,
while the current study evaluated antidementia medication use longitudinally, and unlike
the current study, neither Gruber-Baldini et al. nor Rattinger et al. accounted for the
severity of dementia symptoms.
Mielke et al. (2012) employed an alternative way to calculate usage of
antidementia medications. The persistency index was developed to show the amount of
drug exposure, and in DPS 21.1% of participants with AD regularly used ChEIs (Mielke
et al., 2012). In those analyses, persistency of antidementia use was a significant
predictor of dementia progression, but with divergent effects by gender. It may be that an
approach that considered duration of antidementia use may have been a useful analysis in
the present study. A final limitation to this study is related to the homogeneous nature of
the Cache County Study participants, with being 99% White. While this is representative
of the population of older adults in the county in 1995, generalizability of current
findings to populations with greater ethnic minority representation, particularly with
respect to use of antidementia medications, may be limited.
This project examined total severity of NPS. An area of future research is to
examine specific cluster scores of similar/correlated NPI symptoms. Research has found
that within the CCSMA data approximately 60% of individuals with AD reported one
NPS or more, and of those who reported experiencing an NPS, specific clusters of
symptoms were found to exist including psychotic, affective, and other neuropsychiatric
disturbance (Lyketsos et al., 2001). An examination of cluster scores could identify
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specific symptoms affected by antidementia medications. As previously mentioned,
Cumbo and Ligori (2014), found that the largest improvements in NPS were found in
agitation and aggression for participants using memantine or rivastigmine (Cumbo &
Ligori, 2014). In view of the significant burden associated with NPS, future research
could explore risk factors for NPS. Steinberg et al. (2006) for example, found that gender,
age, dementia severity, APOE E4 allele, dementia diagnosis, time of observation, and
general medical health influenced NPS. An example of an association was that dementia
severity increased the risk of hallucinations and agitation but decreased the risk of
depression (Steinberg et al., 2006). An additional factor that may affect NPS is caregiving
style and caregiver relationship closeness. Research has shown that different caregiving
styles and level of caregiver/care-recipient closeness were associated with progression of
AD, specifically cognitive decline (Norton et al., 2009, 2013). An examination of these
factors and their effects on NPS would be of interest.
While there are numerous short-term studies (less than 1 year) and RCTs, the
current longitudinal, observational study is one of few studies with follow-up data up to
16 years. The current findings of the high correspondence of use of antidementia and
psychotropic medications reveals information about patterns of use, suggesting the
possibility that participants and their caregivers turn to their health care providers to seek
treatment when experiencing more severe dementia or when NPS emerge. An area of
future work would be to examine whether earlier initiation of antidementia medications
may decrease or delay the onset of NPS.
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CHAPTER 4
CONCLUSIONS
The purpose of this study was to evaluate how antidementia medications affect
the occurrence and severity of NPS and the informal costs of care. The literature is
unclear whether cognitive abilities, functional impairment, or NPS are the most
significant factor in increasing the cost of dementia care, but there is evidence that all
contribute to higher informal costs. Results found antidementia medication use was not
associated with informal costs, but when restricting the sample to individuals with mild
dementia at baseline, antidementia medications were associated with lower informal
costs. While the literature has suggested that antidementia medications may potentially
reduce NPS, the current study did not support these findings. In fact, the concurrent use
of antidementia and psychotropic medications was common and that both were
associated with worse NPS. These results suggest that use of one or both classes of these
medications may reflect greater severity of dementia; dementia severity was a significant
contributor to informal costs.
The literature is mixed with respect to the effects of antidementia mediations on
NPS, with many studies differing in the type of antidementia medication studied, duration
of study, control for psychotropic medication, and location of study (e.g., nursing homes,
private residence). Additionally, this study found that dementia severity, place of
residence, and psychotropic medications all predicted NPS over the course of the study.
Last, the high comorbid use of psychotropic medications with antidementia medications
suggest that future studies examine patterns of use and at minimum, control for the use of
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psychotropic medications in statistical models.
The present study examined persons with dementia for up to 16 years, with most
individuals being followed from a few years of dementia onset up to their deaths. Most
research on antidementia medications consists of RCTs, which may limit the
generalizability due to strict eligibility criteria. Being an observational, population-based
study likely makes the results more generalizable to other samples of community
dwelling residents with dementia and provides valuable information of the nature of
antidementia medication use and the costs of informal care over the entire course of
dementia.
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Appendix A
Medication Record from the Cache County Study on Memory in Aging
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Appendix B
Anticholinergic Cognitive Burden Scale

84
Drugs with ACB Score of 1
Generic Name
Brand Name
Alimemazine
Theralen™
Alverine
Spasmonal™
Alprazolam

Xanax™

Aripiprazole
Asenapine
Atenolol
Bupropion
Captopril
Cetirizine
Chlorthalidone
Cimetidine
Clidinium
Clorazepate
Codeine
Colchicine
Desloratadine
Diazepam
Digoxin
Dipyridamole
Disopyramide
Fentanyl
Furosemide
Fluvoxamine
Haloperidol
Hydralazine
Hydrocortisone
Iloperidone
Isosorbide
Levocetirizine
Loperamide
Loratadine
Metoprolol
Morphine
Nifedipine
Paliperidone
Prednisone
Quinidine

Abilify™
Saphris™
Tenormin™
Wellbutrin™, Zyban™
Capoten™
Zyrtec™
Diuril™, Hygroton™
Tagamet™
Librax™
Tranxene™
Contin™
Colcrys™
Clarinex™
Valium™
Lanoxin™
Persantine™
Norpace™
Duragesic™, Actiq™
Lasix™
Luvox™
Haldol™
Apresoline™
Cortef™, Cortaid™
Fanapt™
Isordil™, Ismo™
Xyzal™
Immodium™, others
Claritin™
Lopressor™, Toprol™
MS Contin™, Avinza™
Procardia™, Adalat™
Invega™
Deltasone™, Sterapred™
Quinaglute™
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Ranitidine
Risperidone
Theophylline
Trazodone
Triamterene
Venlafaxine
Warfarin

Zantac™
Risperdal™
Theodur™, Uniphyl™
Desyrel™
Dyrenium™
Effexor™
Coumadin™

Drugs with ACB Score of 2
Generic Name
Brand Name
Amantadine
Symmetrel™
Belladonna
Multiple
Carbamazepine
Tegretol™
Cyclobenzaprine Flexeril™
Cyproheptadine
Periactin™
Loxapine
Loxitane™
Meperidine
Demerol™
Methotrimeprazine Levoprome™
Molindone
Nefopam
Oxcarbazepine
Pimozide

Moban™
Nefogesic™
Trileptal™
Orap™
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Drugs with ACB Score of 3
Generic Name
Amitriptyline
Amoxapine
Atropine
Benztropine
Brompheniramine
Carbinoxamine
Chlorpheniramine
Chlorpromazine
Clemastine
Clomipramine
Clozapine
Darifenacin
Desipramine
Dicyclomine
Dimenhydrinate
Diphenhydramine
Doxepin
Doxylamine
Fesoterodine
Flavoxate
Hydroxyzine
Hyoscyamine
Imipramine
Meclizine
Methocarbamol
Nortriptyline
Olanzapine
Orphenadrine
Oxybutynin
Paroxetine
Perphenazine
Promethazine
Propantheline
Propiverine
Quetiapine
Scopolamine
Solifenacin
Thioridazine
Tolterodine
Trifluoperazine
Trihexyphenidyl
Trimipramine
Trospium

Brand Name
Elavil™
Asendin™
Sal-Tropine™
Cogentin™
Dimetapp™
Histex™, Carbihist™
Chlor-Trimeton™
Thorazine™
Tavist™
Anafranil™
Clozaril™
Enablex™
Norpramin™
Bentyl™
Dramamine™, others
Benadryl™, others
Sinequan™
Unisom™, others
Toviaz™
Urispas™
Atarax™, Vistaril™
Anaspaz™, Levsin™
Tofranil™
Antivert™
Robaxin™
Pamelor™
Zyprexa™
Norflex™
Ditropan™
Paxil™
Trilafon™
Phenergan™
Pro-Banthine™
Detrunorm™
Seroquel™
Transderm Scop™
Vesicare™
Mellaril™
Detrol™
Stelazine™
Artane™
Surmontil™
Sanctura™
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Appendix C
General Medical Health Rating (GMHR)
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SECTION V: GMHR RATING SUBJECT
RESIDENCE
1
HOME/OUTPATIENT
2
RESIDENTIAL/ASSISTED LIVING-UNLOCKED UNITS
2.1 ASSISTED LIVING-LOCKED UNITS
3
SKILLED NURSING FACILITY
Circle one of the numbers between 1 and 4 using the instructions next to each
number. Please begin at the top and decide if the person meets each rating in
sequence as written. If you are having trouble deciding between two adjacent ratings,
rate the lower number.
no current unstable physical illness, may have 1-2 stable
physical illnesses, is on very few medications, and appears
4
EXCELLENT
healthy and in good physical condition
may have one unstable physical illness that is being treated
or a few controlled physical illnesses, is on few medications,
3
GOOD
and appears no more than mildly ill
more than one unstable physical illness and/or numerous
chronic medical conditions, several medications, appears
2
FAIR
moderately ill
several unstable physical illnesses, several medications,
appears quite ill, probably in need of hospitalization or
1
POOR
terminal/hospital care
Other
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Appendix D
Neuropsychiatric Inventory (NPI)

90
SECTION M: NPI DATA
MA. Delusions
In the last month, has (NAME) had beliefs that you know are not true? For example,
insisting that people are trying to harm (HIM/HER) or steal from (HIM/HER). Has
(HE/SHE) said that family members are not who they say they are or that the house is not
(HIS/HER) home? I’m not asking about mere suspiciousness; I am interested if (NAME)
is convinced that these things are happening to (HIM/HER).
YES (Go DATE OF
ONSET)
......................................
1

NO (GO TO MAA) ... 0

NA (GO TO MAA) .... 9

MAA.

Since (the last time mos/yrs) we saw
(NAME) not including the last month has
(he/she) had any of these beliefs?

#1 CHECKPOINT

IF YES RECORD ONSET
DATE AND DATE
STOPPED THEN GO TO
MA1. IF NO GO TO MA14.

YES

NO

IV

RF

1

0

6

7

ONSET DATE

/

DATE STOPPED

/

DK

NA

8

9

MB. Hallucinations
In the last month, did (NAME) have hallucinations such as false visions or voices? Does
(HE/SHE) seem to see, hear or experience things that are not present? By this question
we do not mean just mistaken beliefs such as stating that someone who has died is still
alive; rather we are asking if (NAME) actually has abnormal experiences of sounds or
visions.
YES (Go DATE OF ONSET) 1

NO (GO TO MBB).. 0

NA (GO TO MBB) ...9

MBB.

Since (the last time mos/yrs) we saw
(NAME) not including the last month has
(he/she) had any of these experiences?

#3 CHECKPOINT

IF YES RECORD ONSET
DATE AND DATE STOPPED
THEN GO TO MB1. IF NO
GO TO MB12.

YES

NO

IV

RF

1

0

6

7

ONSET DATE

/

DATE STOPPED

/

DK

NA

8

9
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Appendix E
Caregiver Activity Survey (CAS)
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SECTION C: CAREGIVER ACTIVITY SURVEY (CAS)
C1. Communicating with (NAME)
4.
Looking after one’s appearance
Thinking back over the past day,
Thinking back over the past day,
how much time did you and others
how much time did you and others
spend in the last 24 hours (day and
spend in the last 24 hours (day and
night) doing these types of
night) doing these types of
activities?
activities:
 answering the same question
 reminding the person to
again and again
brush their teeth, brush their
hair, apply cosmetics, shave
 trying to make sense of what
or care for nails
the person says
 helping the person to groom
 leaving reminders for the
 setting out items for
person
grooming activities
hours
minutes
 supervising grooming
activities
hours
2.

Dressing
Thinking back over the past day,
how much time did you and others
spend in the last 24 hours (day and
night) doing these types of
activities;
 reminding the person to
dress
 choosing what to wear
 laying out clothes
 helping the person to dress
or undress
 supervising the person
dressing
 keeping the person from
undressing at the wrong time
hours

minutes

5.

minutes

Supervising the person
Thinking back over the past day,
how much time did you and others
spend in the last 24 hours (day and
night) doing these activities?
 keeping an eye on the person
to be sure that they do not
wander off or get into some
kind of difficulty
 looking out for the person
 preventing the person from
getting lost
 finding the person if they get
lost
hours

minutes

100
3.

Eating
Thinking back over the past day,
how much time did you and others
spend in the last 24 hours (day and
night) doing these type of activities:
 reminding the person to eat
 setting up utensils and food
 cutting or arranging food on
the plate
 supervising or encouraging
the person to eat
 cleaning the person after
eating
hours

C7.

minutes

Completed By____________________ Certification License ________________
Staff Position_______________________
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Appendix F
Neuropsychiatric Inventory Score by Visit
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Figure F1. Neuropsychiatric Inventory Score visit 0.

Figure F2. Neuropsychiatric Inventory Score Visit 1.
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Figure F3. Neuropsychiatric Inventory Score Visit 2.

Figure F4. Neuropsychiatric Inventory Score Visit 3.
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Figure F5. Neuropsychiatric Inventory Score Visit 4.

Figure F6. Neuropsychiatric Inventory Score Visit 5.
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Figure F7. Neuropsychiatric Inventory Score Visit 6.

Figure F8. Neuropsychiatric Inventory Score Visit 7.
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Figure F9. Neuropsychiatric Inventory Score Visit 8.

Figure F10. Neuropsychiatric Inventory Score Visit 9.

107

Figure F11. Neuropsychiatric Inventory Score Visit 10.

Figure F12. Neuropsychiatric Inventory Score Visit 11.
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Figure F13. Neuropsychiatric Inventory Score Visit 12.

Figure F14. Neuropsychiatric Inventory Score Visit 13.
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Figure F15. Neuropsychiatric Inventory Score Visit 14.
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Appendix G
Natural Log Transformation of Neuropsychiatric Inventory
Score by Each Visit
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Figure G1. Natural log of the Neuropsychiatric Inventory score visit 0.

Figure G2. Natural log of the Neuropsychiatric Inventory score visit 1.
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Figure G3. Natural log of the Neuropsychiatric Inventory score visit 2.

Figure G4. Natural log of the Neuropsychiatric Inventory score visit 3.
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Figure G5. Natural log of the Neuropsychiatric Inventory score visit 4.

Figure G6. Natural log of the Neuropsychiatric Inventory score visit 5.
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Figure G7. Natural log of the Neuropsychiatric Inventory score visit 6.

Figure G8. Natural log of the Neuropsychiatric Inventory score visit 7.
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Figure G9. Natural log of the Neuropsychiatric Inventory score visit 8.

Figure G10. Natural log of the Neuropsychiatric Inventory score visit 9.
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Figure G11. Natural log of the Neuropsychiatric Inventory score visit 10.

Figure G12. Natural log of the Neuropsychiatric Inventory score visit 11.
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Figure G13. Natural log of the Neuropsychiatric Inventory score visit 12.

Figure G14. Natural log of the Neuropsychiatric Inventory score visit 13.
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Figure G15. Natural log of the Neuropsychiatric Inventory score visit 14.

Figure G16. Natural log of the Neuropsychiatric Inventory score visit 15.

